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ABSTRACT OF THE THESIS
A DESCRIPTIVE CORRELATION OF MEDICATION AND DIETARY
COMPLIANCE BELIEFS WITH FUNCTIONAL LIMITATIONS IN HEART
FAILURE PATIENTS
by
Dorothy B. Diener
Florida International University, 2000
Miami, Florida
Professor Luz Porter, Major Professor
In order to determine the existence of a relationship between heart failure patients'

compliance beliefs and functional limitations, using a convenience sample of 61 adults
attending a specialized outpatient heart failure clinic, responses to scale items measuring

perceptions of benefits and barriers to compliance with medication and diet were collected
and functional limitations were self ranked by symptoms experienced with activities of
daily living. A positive correlation (Spearman's rho=0.345, p=.007, level of significance

=.0l) between patients' functional limitations and perceived benefits to medication
compliance scores was found while a negative correlation (Spearman's rho= -0.310,

p=.015, level of significance =.05) between functional limitations and perceived barriers
to medication compliance scores was found. Patients' functional limitations correlated
with neither benefits nor barriers to diet compliance scores. It is recommended that nurses
assess and utilize heart failure patients' functional limitations to individualize interventions

aimed at influencing compliance beliefs.
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CHAPTER I
INTRODUCTION

PROBLEM AREA
The broad aim of this study is to shed light on the complex, human behavioral
response set of compliance and what may influence it. Compliance with treatment
regimen in chronic illness, particularly heart failure, is my locus of concern.

I became interested in the concept of compliance with frequent clinical exposure to
examples of noncompliance when working as a geriatric medical/surgical nurse. I found
the consequent physical, psychosocial and financial costs associated with noncompliance
to be exorbitant.
My current work in cardiac and cardiovascular intensive care frequently brings the
chronically ill heart failure client into my sphere of influence. This patient presents a

wealth of opportunities for health promotion. Ultimately, patient educational interventions
aimed at improving self management of chronic illness may improve patient quality of life.
In 1994, the Agency for Health Care Policy and Research Clinical Practice Guideline
(Konstam et al., 1994) stated that almost one million Americans were hospitalized

annually with heart failure and suffered a five year mortality rate in the range of 50
percent. In 1990, 10 billion dollars in total treatment costs were assessed for heart failure
(Konstam et aL., 1994). The American College of Cardiology and the American Heart
Association (ACC/AHA) Task Force reported 4,700,000 Americans diagnosed with
congestive heart failure and a six year mortality rate approaching 80 percent in men and 65

percent in women (ACC/AHA Task Force, 1995). Both publications warned of increasing
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incidence and mortality rate as the United States population ages, an alarming prediction

(ACC/AHA Task Force, 1995; Konstam et al., 1994).
The Centers for Disease Control and Prevention (CDCP) explained increases in CHF
(congestive heart failure) death rates and hospitalization rates among older age groups
from 1980-1990 with "increasing average age of the U.S. population and the longer
survival of persons with hypertension or symptomatic cardiac diseases who subsequently
develop CHF at an older age" (1994, p.79). Calls to action include the need for more
population-based data to assess trends in incidence, survival, management practices and
application of treatment strategies for heart failure (Goldberg, 1999; Senn

et

.,

1999).

New practice guidelines for the prevention, diagnosis and treatment of heart failure

have been developed by expert consensus (Advisory Council to Improve Outcomes
Nationwide in Heart Failure/ACTION HF, 1999). The primary focus of these guidelines is
the rapidly changing pharmacologic management of chronic heart failure secondary to left
ventricular systolic dysfunction which accounts for 80 to 90% of heart failure patients.

Today, heart failure is the only major cardiovascular disease of increasing
incidence and prevalence. It is now reported (ACTION HF, 1999) that 4.8 million in the
United States are afflicted with 400,000 to 700,00 new cases of heart failure occuring
annually accounting for approximately 1.5 to 2% of the US population with heart failure.
Approximately 250,000 direct and indirect deaths due to heart failure occur annually

representing a six fold increase in the past forty years of number of deaths due to heart
failure as a primary or secondary cause (ACTION HF, 1999). Twenty to forty billion

dollars in direct expenditures for heart failure in this country annually have been estimated
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with annual hospitalization costs estimated at $8 to $15 billion. Three and a half million

hospitalizations for heart failure occur annually with this clinical syndrome being a leading
cause of hospitalization among people over 65. Discouragingly, approximately 33% of

patients hospitalized for heart failure are readmitted within 90 days (ACTION HF, 1999).
This latest treatment guideline (ACTION HF, 1999) defines goals of treatment

addressing these startling statistics: improve symptoms, improve quality of life, decrease
disease progression, decrease risk of death and decrease need for hospitalization.
Assuming accepted standard therapeutic regimens are efficacious in the management
of this chronic disease, understanding the influences on patient compliance with them may
ultimately serve to lessen the public health burden ascribed to this diagnosis. Health care

practitioners diagnosing heart failure and prescribing treatment are consequently important
to the exploration of patient compliance. If positive patient outcomes like decreased rates
of rehospitalization and the ability to evaluate individual treatment efficacy are practice

goals, then patient compliance with prescribed treatment and what may promote, impede
or relate to that compliance are important practice issues.
A review of the literature related to heart failure patients reveals their clinically
significant rehospitalization rates (Bennett et al., 1998; Ghali, Kadakia, Cooper &

Ferlinz, 1988; Haldeman, Croft, Giles, Rashidee, 1999; Happ, Naylor & Roe-Prior,
1997; Krumholz et al., 2000; Krumholz et al., 1997; Michalsen, Konig &

Thimme, 1998; Opasich et al., 1996; Rich et al., 1995; Shah, Der, Ruggerio, Heidenrich
& Massie, 1998; Struthers, Anderson, Donnan, & MacDonald, 2000; Vinson, Rich,
Sperry, Shah, & McNamara, 1990 ). Precipitant and preventable contributory factors for
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readmission include lack of adherence to prescribed medication and/or dietary regimens as
supported by studies formerly referenced and that of West et al. (1997). Chi and
Goldman (1997) found self reported patient compliance did not correlate with early
hospital readmission or death.
A large body of knowledge has been accumulated regarding compliance as a
phenomenon including its predictors, determinants, measurements and correlates with
Sackett and Haynes' classical work "Compliance with Therapeutic Regimens" remaining a

definitive reference (1976).
A sociobehavioral model for the further study of compliance with therapeutic regimens
was derived by M.H. Becker with modification of the Health Belief Model. This Health
Belief Model grew from origins in Kurt Lewin's Social Science Field Theory and from the
work of social scientists: Hochbaum, Kegeles, Leventhal and Rosenstock in the 1950's

and 1960's (Rosenstock, 1974).
The Health Belief Model (HBM) argues that an individual's perceptions of personal
susceptibility to illness, severity of illness consequences (presence of or past experience

with symptoms), the health action's benefits ( effective reduction or prevention of
susceptibility/severity) , and barriers related to undertaking the health actions (physical,

psychological or financial costs) will influence whether or not an individual will undertake
a recommended health action (Becker, 1974). Based on this Model, scales were developed
to measure heart failure patients' beliefs (perceived benefits and barriers ) regarding
medication and dietary compliance (Bennett, Milgrom, Champion & Huster, 1997).
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PURPOSE
The purpose of this study was to measure beliefs about medication and dietary

compliance in heart failure patients in a South Florida health care program using the
instrument developed by Bennett et al. (1997). These investigators suggested that heart
failure patients' compliance beliefs may differ according to their classification level of
disease. Bennett et al. stated that "beliefs about compliance might be different for patients
with varying classes of heart failure because of the differences in heart failure related

symptoms" (1997, p.278). In order to determine the existence of a relationship between
compliance beliefs and heart failure class, participating patients were asked to report
functional limitations indicating presence of or experience with symptoms (Becker, 1974;
Bennett et a., 1997).

PROBLEM STATEMENT
To what extent do therapeutic regimen compliance beliefs relate to functional

limitations in heart failure patients enrolled in a specialized, outpatient heart failure clinic?
1. What are the beliefs about medication compliance among heart failure patients?
1.1 What are perceived benefits to medication compliance?

1.2 What are perceived barriers to medication compliance?
2. What are the beliefs about dietary compliance among heart failure patients?
2.1

What are perceived benefits to dietary compliance?

2.2 What are perceived barriers to dietary compliance?
3. What are the functional limitations among heart failure patients?
4. What is the relationship between function limitations and:

5

4.1a. Beliefs about Medication Compliance/perceived benefits

4.1b. Beliefs about Medication Compliance/perceived barriers
4. 2a. Beliefs about Dietary Compliance/perceived benefits
4. 2b. Beliefs about Dietary Compliance/perceived barriers
DEFINITION OF TERMS
HEART FAILURE
Heart failure is a clinical syndrome or condition characterized by (1) signs and
symptoms of intravascular and interstitial volume overload, including shortness of
breath, rales, edema, or (2) manifestations of inadequate tissue perfusion, such as
fatigue or poor exercise tolerance.These signs and symptoms result when the heart
is unable to generate a cardiac output sufficient to meet the body's demands
(Konstam et al., 1994, p.11).
BELIEFS. Beliefs refer to the individual heart failure patient's perceptions about

compliance with medication and dietary regimen. These perceptions are measurable and
tend to stratify along two axes; benefits of and barriers to compliance with therapeutic
regimen (Bennett et al., 1997).

COMPLIANCE. "the extent to which the patient's behavior coincides with the
clinical prescription, regardless of how the latter was generated" (Sackett & Haynes,

1976, p.2).
BENEFITS. Perceived benefits are "belief in the efficacy or value of a behavior in
reducing the threat" posed by illness ( Becker, Maiman, Kirscht, Haeffer & Drachman,

1975, p. 349).
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BARRIERS. Perceived barriers are "estimates of physical, psychological, financial
or other costs involved in the proposed action" (Becker, Maiman, Kirscht, Haefler &

Drachman, 1975, p.349).
FUNCTIONAL LIMITATIONS. The Agency for Health Care Policy and Research
Clinical Practice Guideline (Konstam et aL., 1994) utilizes the New York Heart
Association (NYHA) four tier classification system (I-IV) to define increasing states of

functional limitation in cardiac disease patients:
NYHA levels (of functional limitation) can be described as follows:

I--Cardiac disease without resulting limitations of physical activity
II--Slight

limitation of physical activity--comfortable at rest, but ordinary physical

activity results in fatigue, palpitation, dyspnea, or anginal pain
III--Marked limitation in physical activity--comfortable at rest, but less than
ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain
IV--Inability to carry on any physical activity without discomfort or symptoms at
rest.

Although criticized for a lack of reliability, this system is still widely used (p.43).
SIGNIFICANCE
A highly symptomatic heart failure patient reporting marked functional limitation
may perceive greater susceptibility to illness or severity of illness consequences than the
asymptomatic, functionally capable heart failure patient. A more symptomatic patient may
perceive their therapeutic regimen differently. If self reported functional limitations
designating heart failure class may be related to therapeutic regimen compliance beliefs,
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both may influence whether or not an individual will undertake a recommended health

action (Becker, 1974).
Assessing and utilizing heart failure patient's beliefs about compliance and factors that
relate to those beliefs may allow practitioners to better individualize educational
interventions that ultimately increase compliance with medication and dietary regimen
treating this incurable disease.
The significance of this study stems from its attempt to both describe and explore
what may potentially influence compliance with treatment in the practical management of
a costly chronic illness. Increased compliance with therapeutic regimen may maximize the

individual's health potential by both promoting better health and preventing acute
decompensation and rehospitalization in the heart failure patient.

CHAPTER II
REVIEW OF THE LITERATURE

A literature review was undertaken to elucidate heart failure and compliance with
medication and diet as factors in patient decompensation. The pathophysiology of this

chronic disease, current treatment guidelines and new management strategies promoting
therapeutic regimen compliance were also reviewed.
PATHOPHYSIOLOGY
McKee, Castelli, McNamara and Kannel (1971) performed retrospective analyses of
Framingham study subjects; a classic, epidemiologic study, "coded for the presence of
congestive heart failure during the preceding 16 years" (p.1441). As evidenced by 75
percent of studied cases, congestive heart failure development was found most frequently
preceded by hypertension and demonstrated high mortality rates with probability of death
five years following onset at 62 percent for males and 42 percent for females (McKee et
al., 1971). In this cohort of 5,192 persons initially free from disease, 3.5 percent of males
and 2.1 percent of females developed overt myocardial insufficiency within 16 years; then
noted as "far from trivial" (McKee et al., 1971, p.1444). The magnitude of this health
problem is formally realized here. The burden of this disease entity was then and is now
only expected to increase as the United States geriatric population increases (ACC/AHA
Task Force, 1995; Konstam et al., 1994; McKee et al., 1971).
The 1980's saw the investigation of the roles of several neuroendocrine systems in
relationship to the hemodynamics of heart failure denoting a marked change in study
focus from the previous half century (Cody et a., 1989; Francis et a., 1990; Levine et al.,

1982). The pathophysiology of heart failure had been described primarily in hemodynamic
terms alone secondary to ventricles unable to pump the demanded blood supply to the

periphery (Packer, 1992).
A delicate balance of hemodynamic and neurohormonal mechanisms serve to
compensate the failing heart. However, "long-term activation of endogenous positive,
inotropic and stress-reducing mechanisms leads to a diminuition of their favourable

physiological effects" (Packer, 1992, p.89).
It has been found that even before overt, symptomatic heart failure, in the earliest
stages of left ventricular dysfunction, activation of vasoconstriction and vasodilation
mechanisms occur (ACC/AHA Task Force, 1995; Francis et al., 1990; Hsu, 1996). As the
failing heart decompensates in an effort to support systemic perfusion and perfusion
pressures, sustained neurohormonal activation results in peripheral vasoconstriction, and
sodium and water retention. Counter regulatory vasodilatory mechanisms in the kidney
and periphery are lost. This counter regulatory loss further compounds the loss of

compensatory myocardial mechanisms decreasing subsequent ability to maintain cardiac
output (Packer, 1992).
There is biochemical evidence of sympathetic activation in heart failure with

deleterious effects as follows: beta receptor down regulation, myocardial remodeling,
cardiotoxic changes, associated ventricular arrhythmias and immunologic alterations with
response deficits induced by increased sympathetic activity. Mortality has been shown to
correlate to measurements of circulating catecholamines in heart failure patients (Pepper &

Lee, 1999).
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In short, the pathophysiology of heart failure is complex with compensatory

biochemical pathways. Without support, these mechanisms are eventually overwhelmed
and decompensation is inevitable. Thereby a low sodium diet and cardiovascular

medications are integral to the long term management of this chronic illness. Therapeutic
regimen comprised of medication and low sodium diet serve to complement and support

the body's compensatory efforts aiding the failing heart (ACTION HF, 1999; ACC/AHA
Task Force, 1995; Hsu, 1996).
TREATMENT GUIDELINES
It is the evolving pathophysiology of heart failure that shapes its medical

management. Hsu (1996) purports the following treatment principles to guide heart failure
management: "eliminate precipitating factors of heart failure, decrease myocardial

workload, increase myocardial contractility, decrease sodium and water retention and
facilitate ventricular relaxation" (p.96). Cohn (1996) emphasizes targeting those

"therapeutically modifiable mechanisms" of heart failure progression in the fight to
prolong life, namely:

vasoconstriction due to neural, hormonal, or endothelial factors that increase the
impedance load on the left ventricle; activation of the sympathetic nervous system and
the renin-angiotensin system, which can stimulate the growth of tissue in the
myocardium and the peripheral vasculature; neurohormonal or tissue induced

mechanisms that have direct toxic effects on myocytes; progressive enlargement or
remodeling of the left ventricle; local or circulatory influences that induce ventricular
arrhythmia; and thromboembolic events (p.494).

Practice standards for medical management of heart failure today incorporate these
principles.
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The clinical practice guideline "Heart failure: Evaluation and care of patients with left
ventricular systolic dysfunction" (Konstam et aL., 1994), the ACC/AHA Task Force

report "Guidelines for the evaluation and management of heart failure" (1995) and the
"Consensus recommendations for the management of chronic heart failure" (ACTION HF,
1999) comprise the currently accepted evaluation and treatment standards for heart failure

in the United States. These guidelines are research based and derived from expert
consensus opinion serving to steer clinical practice decisions for the sound

medical management of heart failure.
Regarding diet as a management intervention in heart failure, these expert references
cite sodium restriction as integral. Konstam et aL. (1994) advise dietary sodium intake
restriction from two grams to a strict three grams, daily. ACC/AHA Task Force (1995)
cites sodium restriction as a critical treatment strategy. ACTION HF (1999) recommends
as a general treatment measure, moderate daily sodium intake (less than or equal to 3

grams daily) with daily weight monitoring to effectively utilize lower, safer diuretic doses.
Other, secondary, authoritative sources concur that dietary sodium excess is a precipitant
factor in heart failure and should be restricted (Aronow, 1997; Dracup, Baker, Dunbar et
al., 1994; Hsu, 1996; Karon, 1995).
Regarding pharmacologic management, angiotensin converting enzyme (ACE)
inhibitors are sole treatment for an indefinite time period if well tolerated and patient is
only symptomatic with fatigue or mild exertional dyspnea or is asymptomatic with
significant left ventricular systolic dysfunction (an ejection fraction less than 35-40

percent) (ACTION HF, 1999; ACC/AHA Task Force, 1995; Konstam et al., 1994; The
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SOLVD investigators, 1991). ACE inhibitors conserve potassium and relieve symptoms

by reducing aldosterone secretion (Cohn, 1996).
Hydralazine and isosorbide dinitrate is an acceptable alternative if ACE inhibitors are
contraindicated or poorly tolerated (ACC/AHA Task Force, 1995; Konstam et aL, 1994).
In some cases of heart failure with abnormal left ventricular ejection fraction, hydralazine
and isosorbide dinitrate as vasodilator therapy, may be used in combination with ACE

inhibitors (Aronow, 1997; Cohn et a]., 1991).
If the patient remains symptomatic with ACE inhibitors and a low sodium diet, or for

any overt signs or symptoms of volume overload, diuretics are added to the regimen and
continued (even when edema free) with dosage and type adjustments (ACC/AHA Task
Force, 1995; Konstam et al., 1994). Diuretics are a "therapeutic cornerstone" and are the
"only reliable means of controlling fluid retention of heart failure" ( ACTION HF, 1999,
p.12A). Diuretics are important as a class for their ability to alter efficacy and toxicity of
nearly all other drug therapies used to treat heart failure; a necessary though insufficient

therapy (ACTION HF,1999).
Since this literature review was initiated, beta blockers are now recommended for use

in NYHA Class II or III heart failure secondary to left ventricular systolic dysfunction
with diuretics and ACE inhibitors. These drugs may reduce risk of disease progression
even if no symptom decrease is realized (ACTION HF, 1999).

Digoxin is recommended to improve clinical status with heart failure secondary to left
ventricular systolic dysfunction in concert with diuretics, ACE inhibitors and beta
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blockade therapy (ACTION HF, 1999) and in patients with rapid ventricular response
rates secondary to atrial fibrillation (ACC/AHA Task Force, 1995; Konstam et al., 1994;

The Digitalis Investigation Group, 1997).
Anticoagulants are recommended for patients with atrial fibrillation or a history of
pulmonary or systemic embolism. Mild to moderate exercise like walking or recreational
bike riding is encouraged to prevent/reverse physical deconditioning. Overexertion is to be

avoided (ACTION HF, 1999; ACC/AHA Task Force, 1995; Konstam et al., 1994).
On first literature review, the use of carvediol (an alpha 1 and beta 2 adrenergic
blocker) and losartan, (an angiotensin II receptor antagonist) were both noteworthy for
conferring some symptomatic relief without adverse mortality outcomes (Packer et al., 1
1996; Pitt et al., 1997). Now, as mentioned, beta blockade is incorporated into

recommended treatment guidelines and no persuasive evidence has demonstrated
angiotensin II receptor antagonists equivalency or superiority to ACE inhibitors in the
treatment of heart failure. Large scale trials of drugs in both categories are in progress
(ACTION HF, 1999).
Investigational research for effective medications to reduce morbidity and mortality
in heart failure patients remains ongoing. The fact also remains, that short of cardiac
transplantation, there is no cure for heart failure. Appropriate prescription of efficacious

treatment to informed, compliant heart failure patients engenders their maximum health
potential. "Current therapy for heart failure can maintain function, improve quality of life
and prolong survival" notes Dracup, Baker, Dunbar et al., (1994).

The best pharmacologic and dietary treatment regimens are only efficacious if heart
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failure patients comply with them. Konstam et a., (1994) cite noncompliance as a major

cause of morbidity and hospitilization in heart failure. Their clinical practice guideline
emphasizes practitioner awareness of noncompliance and its causes as integral to the
successful management of heart failure patients (1994). "Although it is clear that
noncompliance is a major problem in caring for patients with heart failure, it is less clear
what should be done to improve this situation" (Konstam et al., 1994, p.147).

"Noncompliance with diet and medication can rapidly and profoundly affect the clinical
status of patients..." (ACTION HF, 1999, p.1 A).
COMPLIANCE WITH THERAPEUTIC REGIMEN
Patients' beliefs concerning their susceptibility to disease and the benefits and barriers
to therapy are conceptual dimensions of the Health Belief Model (HBM). These
potentially related dimensions are also empirically measurable variables and are central to

the assessment of the chronically ill heart failure patient. Maiman, Becker, Kirscht,
Haelner and Drachman (1977) applied the HBM to chronic illness behavior performing
multivariate testing to its major dimensions, developing reliable scales for dimension

measurements and explicating relationships among beliefs. This study provided a rich,
descriptive assessment of HBM dimensions and relationships to long term therapeutic

regimen (diet modification). Individuals' compliance behaviors correlated with measured
health beliefs (Maiman et al., 1977).
Jenkins (1979) considered problems of health related behavior as symptoms and

advocated making a behavioral diagnosis. As always, a diagnostic process is begun with
careful assessment. The HBM concepts including perceived severity/susceptibility, benefits
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and barriers were advocated for use as a guide to explore the full nature and history of
noncompliance. "If the barier to health promoting behavior is a lack of appropriate

information or an incorrect belief system, the health worker's intervention will focus on
successful communication" (p.13).

Given, Given, Gallin and Condon (1983) constructed scales to measure chronically ill
diabetic patients' beliefs about their disease and therapy using HBM concepts as a
framework also.
These scales represent a useful tool for transferring greater responsibility to patients

for the management of their diabetes. This process should begin with an assessment of
patients' beliefs about such issues as their ability to control the effects of diabetes, the
barriers to, as well as support for carrying out therapy, and their beliefs regarding that

therapy (p.140).
Given et

. (1983) asserted psychosocial assessment as a necessary first step to

constructing behavioral interventions for increasing patient involvement in the
management of their chronic illness.
In 1985, Becker reviewed the state of the art for research regarding patient adherence
to prescribed therapies. He asserted "that efforts to enhance patient regimen adherence
should attend to the attitude and belief dimensions of the HBM in addition to other likely
influences on health-related behavior" (p.544).

Redeker (1988) focused on a review of the literature regarding compliance issues
specific to chronic illness and health beliefs. Further development and testing of valid and

reliable tools for nursing assessment in these areas is called for. This work and further
study of interaction among HBM variables was asserted as essential and preliminary to the
testing of interventions designed to support compliance behaviors.
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In 1979, R.B. Haynes wrote in introduction of the work "Compliance in Health
Care" that "it is no longer possible to execute an exhaustive review of the scientific
literature on compliance" (p.6). Apparently, since the dawn of medicine, compliance with
therapeutic regimen has been a part of the human condition. Haynes (1979) references

Hippocrates who warns fellow physicians to remain mindful of patients frequently lying
when queried regarding medication compliance!
The literature on compliance with therapeutic regimen is vast. Its most consistent

elements remain its inherent complexity and controversy as a human behavioral response.
Seminal to this research work and indivisible from the study of all compliance issues is
Sackett and Haynes' (1976) "Compliance with Therapeutic Regimen". This edited work
was the outgrowth of a symposium held at McMaster's University in 1974. The authors
reviewed the existing literature to that time with strict scientific rigor and their many
findings remain often-quoted as central tenets to compliance studies even today.

In an attempt to assess the magnitude of compliance and noncompliance, many
inconsistencies were revealed secondary to the mechanics of study like design, sampling
and how compliance was operationally defined. A distinction important to the hypotheses
of this work emerged. Symptomatic patients showed higher rates of compliance with their
therapeutic regimens, regardless of how that compliance was operationalized (Sackett and

Haynes, 1976).
Many factors were studied in relationship to compliance including patient
demographics and sociobehavioral features, disease features, features of the therapeutic

regimen and the interaction between patient and therapist. Demographics were noted to
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more generally affect access to health care rather than compliance withherapy.
Psychiatric diagnoses were found to have a negative association with compliance behavior.

Reduced compliance was associated with three regimen features: (a) greater complexity,
(b) greater patient behavioral changes, and (c) longer continuance over time. Continuity
of care with regular providers and reduced waiting times for pharmacy, appointments and
referrals are positively associated with compliance. A high degree of care provider
supervision with the regimen is also positively associated with compliance (Sackett and

Haynes, 1976).
Patient dissatisfaction with care provider interaction is associated with
noncompliance. Previous or present noncompliance with other regimens is also associated
to non compliance with a particular recommendation. Family instability and innapropriate

health beliefs were also associated with noncompliance (Sackett and Haynes, 1976).
The Health Belief Model which will be fully explored as the conceptual/theoretical
framework for this study, was shown by Sackett and Haynes (1976) to have predictive
value with both prospective and retrospective compliance studies. Prospective studies

showed weaker relationships with the model suggesting changes in compliance behavior
may precede not follow changes in patients' health beliefs.
Other important conceptual issues such as strategies to improve compliance were
reviewed and criticized in this classic work. Methodologic issues important to compliance

research including compliance measures and their correlation with treatment goals were
also explored having been identified as impediments to the development of new

knowledge (Sackett and Haynes, 1976).
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Romm, Hulka and Mayo (1976) undertook a study of 122 congestive heart failure
patients to correlate health care process measures with patient outcome measures. The
patient group with less symptomatology initially, had a process measure in the
doctor-patient relationship realm positively related to outcome. Overall, the best predictor
of final health status was initial health status and not those measured aspects of the
process of care.
Hulka, Cassel, Kupper and Burdette (1976) selected a stratified random sample of 46
physicians and their respective heart failure patients enrolled for study when visiting their

participant physician. Characteristics of medication regimen, doctor-patient
communication affecting patient medication taking behavior and physician awareness of
medication taking behaviors were evaluated. Errors of omission, comission, scheduling
misconception and scheduling noncompliance were defined. Low levels of all error types
were found with good communication of instructions and information from physician to
heart failure patient. Greater errors of omission and commission were associated with
greater number of drugs prescribed in the doctor-patient pair. Greater errors of
commission and scheduling misconceptions were associated with more complex schedules
for administration of medications.
Methods for the evaluation of patient compliance with medication regimen were
often the subject of evaluation. In 1979, Fletcher, Pappius and Harper evaluated the
measurement of patient compliance with prescribed digoxin by interview, pill count and
serum digoxin concentration (SDC). "Interview was more feasible, easier,and more timely
than either pill count or measurement of SDC." (p.637). Compliance measurement by
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interview correlated with SDC's in these patients. Cummings, Kirscht, Becker and Levin
(1989) compared blood chemistries, health professionals' ratings and patients' self reports
for assessing patient compliance with medication regimen. It was concluded that a variety
of measures providing a multifaceted assessment of adherence is the best assurance to

accurately gauge a patient's compliance with therapeutic regimen. The Center for Health
Promotion and Education of the Centers for Disease Control provided new information on
strategies to promote patient self managment of chronic disease (1982). Ethnicity and

number of daily prescribed pills were the only significant predictors from the multivariate
analysis of noncompliance in an evaluation of 249 male veterans (Gravely & Oseasohn,

1991).
DiMatteo et al. (1993) explored the role of the health care provider in promotion of

therapeutic regimen compliance among diabetic, hypertensive and heart disease patients.
Medication and diet adherence was found to decline significantly in this group over the
life of this 2 year longitudinal study. Eleven of 132 comparisons showed statistically
significant positive effects of adherence on health outcomes in the Medical Outcomes
Study (MOS), another notable longitudinal study in 1993. Hays et al. in this 4 year
observational study of 2,125 adult chronic disease patients (including some with heart

failure) concluded that the relationship between health outcomes and adherence with
therapeutic regimens was much more complex than previously assumed.
A retrospective follow up study of 7,247 patients newly prescribed digoxin (as
verified with the complete prescription claims fie of the New Jersey Medicaid program)
revealed only 10 percent of the study population filled enough prescriptions to have this

20

daily heart failure medication available for the entire follow up year (Monane, Bohn,

Gurwitz, Glynn & Avorn, 1994).
Cameron (1996) identified social and psychological factors thought to influence
compliance. Development of a therapeutic relationship and monitoring of compliance
behavior were advocated here.

COMPLIANCE AND REHOSPITALIZATION
In a definitive prospective study of 101 urban heart failure patients, Ghali, Kadakia,
Cooper and Ferlinz (1988) evaluated the frequency and relative importance of precipitant
factors leading to hospital admission for decompensated heart failure. Noncompliance wa
the term used by investigators describing those subjects who stopped taking all their

medications, took medication only intermittently and/or who demonstrated dietary
indiscretion and recent sodium excess prior to worsening symptoms. Noncompliance was
assessed by subjective patient self report of the aforementioned conditions. Twenty two
percent of patients studied were noncompliant with diet alone while 6% of patients were
found noncompliant with medications alone. Noncompliance with both diet and
medications was found in 37 % of patients studied. Noncompliance with entire medical
regimen or any of its parts was the most commonly identified precipitant factor found in

64 % of this study cohort (Ghali et al., 1988).
Of 140 prospectively evaluated hospitalized patients with documented heart failure
surviving an index admission, 47 % (66) were readmitted within 90 days (Vinson, Rich,
Sperry, Shah, & McNamara, 1990). Readmissions were evaluated by diagnosis, reason
and preventability. Dietary or medication noncompliance deemed avoidable by improved
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patient education or medication review were thereby categorized as remediable factors

contributing to potentially preventable readmissions. Medication noncompliance
contributed to 15 % of readmissions and diet noncompliance contributed to 18 % of
readmissions respectively in this 90 day evaluation (Vinson et aL., 1990).
Opasich et al. (1996) prospectively evaluated 304 heart failure patients referred to a
specialized unit for care in Italy. "Decompensation was defined as a worsening of NYHA
class associated with the need for an increase in medical treatment (at minimum,
intravenous diuretics). Only nonfatal decompensations were considered" (p.354). Three
hundred twenty eight decompensations were identified by direct observation, case history

and clinical records. Lack of adherence to prescribed medical and nonmedical regimens
was found in 15 % of decompensations. Therapeutic strategies incorporating preventive
measures for these potentially precipitant factors were called for by investigators.

Krumholz et al. (1997) conducted an observational study in Connecticut using
Medicare administrative files and found that 7,596 patients or 44 % of 17,448 survivors o

index hospitalization for heart failure were readmitted within 6 months of that index
admission. Clarification of readmission determinants was called for by the investigators.
Happ, Naylor and Roe-Prior (1997) undertook a notable qualitative evaluation of
advanced practice nurse (APN) logs, physician's notes, medical record summaries,
admission interviews and study questionnairres from the files of 16 elderly heart failure
patients to determine factors contributing to rehospitalization. "Medication adherence

particularly diuretic dosing, was the most commonly identified and most recalcitrant
problem documented by APN's" (p.80).
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Dietary nonadherence themes were expressed as unwillingness or inability to change
diet habits and as dietary indiscretions. Another theme found here and categorized as a
poor health behavior, was a history of nonadherence to treatment regimen prevalent
among the rehospitalized portion of the cohort.
Chin and Goldman (1997) prospectively evaluated 257 hospitalized heart failure

patients, discharged alive from index admission, for readmission or death.
Approximately one third of this cohort was readmitted within 60 days of discharge.
Patient compliance was not correlated with readmission nor death. Investigators
questioned compliance scales for sufficient sensitivity. Most notably, investigators were
unable to identify a truly low risk group within this patient cohort and asked the question:
Is it possible to describe a clinically significant low rate of readmission among heart failure

patients?
Michalsen, Konig & Thimme (1998) prospectively recruited and evaluated during a
one year period, a consecutive sample of 179 acutely decompensated, previously

diagnosed, heart failure patients on hospital readmission. Noncompliance with diet or
drug treatment was most commonly identified as a causative factor accounting for 41.9%
of these cardiac decompensation cases.
Bennett et al. (1998) found compliance with therapeutic regimen difficult to
determine secondary to retrospective record review in a study of 1,992 hospital
admissions for heart failure. Excessive sodium retention was found to be a leading factor
associated wth patient decompensation. Investigators suggested implementation of

behavioral interventions to improve compliance with medication regimen and low sodium
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diet as a means to reduce this decompensation risk.
Krumholz et aL. (2000) retrospectively evaluated 2,176 patients 65 years of age and
older with a primary diagnosis of heart failure on hospital discharge and found 4 of 32
factors examined to be associated with rehospitalization: prior hospital admission within
the year, prior heart failure diagnosis, diabetes mellitus diagnosis and an elevated serum
creatinine level (>2.5mg/dl). Admittedly, due to retrospective nature of the study design,
as in the Bennett et al. study (1998), investigators cite only the ability to evaluate clinical
factors versus psychosocial factors related to rehospitalization risk. As in the Chin and
Goldman study (1997), investigators were unable to identify a group of heart failure

patients at very low risk for readmission suggesting that any elderly patient surviving
admission for heart failure should be considered at risk for readmission.
Outcome measures were for all emergency hospital admissions and for cardiac
emergency admissions with an effort to examine if treatment nonadherence was greater in

socially deprived versus other socioeconomic groups, in a study of 478 chronic heart
failure patients (Struthers, Anderson, Donnan and MacDonald, 2000). All patients had

had previous hospitalization for heart failure, had had myocardial infarction and were on
diuretic therapy. Investigators found that social deprivation increased rehospitalization
chance of the chronic heart failure patient independent of disease severity as judged by
dose of diuretic prescribed. Diuretic adherence was operationalized as the percentage of

time during study when patients had diuretics available at home. As per Struthers et
al.(2000),

diuretic nonadherence could not be dismissed as a potential contributor to

rehospitalization nor could dietary nonadherence secondary to the cross sectional design
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of the study.

NEW MANAGEMENT STRATEGIES
Pearson and Peters (1997) describe the known treatment gap between guidelines for risk
reduction and disease management in coronary artery disease and heart failure patients and
the actual care these patients are receiving. Inpatient/hospital programs,
specialist/generalist communication, ambulatory care and patient compliance are all
potential barriers playing a part to limit optimal care of these patients thereby creating the
"treatment gap".
In 1992, Buschnell conducted a small descriptive study and found that almost all
participants could not correctly define heart failure and less than half could correctly
identify their medicines. Hagenhoff, Feutz, Conn, Sagehorn and Moranville-Hunziker
(1994) cited the lack of published information regarding learning needs of the heart failure
patient and adapted a tool originally developed for myocardial infarction patients to

measure perceptions about learning needs. Agreement was found between hospitalized
heart failure patients and their nurses that medication information was the most important
and realistic patient education content to be learned.
Nurse directed, multidisciplinary intervention was found to increase quality of life and
reduce hospital use and associated medical costs for elderly heart failure patients in a
prospective, randomized trial of intervention versus conventional care by Rich et
al. (1995). "A multidisciplinary treatment strategy is associated with improved medication

compliance during the first 30 days following hospital discharge in elderly patients with
CHF" (Rich, Gray, Beckham, Wittenberg & Luther, 1996,
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p.270).

Assignment to

intervention group was the strongest independent predictor of medication compliance
with rates significantly higher by pill count assessment for those of the 156 participants

randomized to the study intervention.
Hanumanthu, Butler, Chomsky, Davis and Wilson (1997) found that of 134

patients followed, 94 % were hospitalized during the year before referral versus 44 %
hospitalized during the year after referral intervention managed by heart failure specialists
in a dedicated program (versus management by physicians not specializing in heart failure).
Fewer hospitalizations and greater exercise tolerance were found after

specialized management.
1997 was also notable for the study of Fonarow et al. Two hundred fourteen NYHA

Class III and IV heart failure patients awaiting transplantation experienced significantly
decreased hospital readdmission rates and improved functional status during the 6 month

period following comprehensive management including medical therapy and intensive
education than in the previous 6 month period with no specialized management.
Another comprehensive management system for heart failure was evaluated in 1997
called MULTIFIT by West et al. In a small (51 participants) nonrandomized study, this

home based, nurse mediated and physician supervised program was evaluated. MULTIFIT
implemented consensus guidelines for medication and dietary therapy and close
monitoring by frequent telephone contact. Statistically significant improvements were
found including (a) decreased daily sodium intake (b) increased daily medication doses (c)
functional status and exercise capacity improvements (d) decreased emergency room visits
and hospitalization rates as compared to the previous year before program enrollment.
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Program efficacy may be more conclusively demonstrated with a larger randomized trial.
Laing and Behrendt (1998) described an interactive home health care management
program for heart failure patients without providing any standardized outcomes such as
comparative hospitalization rates pre and post program enrollment with which to objectify
its efficacy versus other interventional programs.
A 27 participant pilot study was also completed in 1998 by Shah, Der, Ruggerio,

Heidenreich and Massie testing an interactive home monitoring program of heart failure
patients. It was suggested here that close telephone monitoring of recently discharged and
ambulatory outpatients could prevent rehospitalizations among these patients.
In a follow up study to this pilot, Heidenreich, Ruggerio and Massie (1999) suggest that a

multidisciplinary program of patient monitoring, education and physician notification
implemented in community practice settings can contribute to decreased hospitalizations
and medical claims in a group of elderly heart failure patients.
In summary, the body of accumulated literature regarding compliance behavior is vast.
Compliance with therapeutic regimen in heart failure is necessitated both by its
pathophysiology and lack of cure. There are efficacious medication and dietary regimens
for heart failure management. Rehospitalization rates for this chronic illness are clinically
and statistically significant. Medication and dietary regimen noncompliance has been
implicated as precipitant in the rehospitalization of heart failure patients. Specialized
management, including strategies to support and promote compliance with therapeutic
regimen, has been found effective in the fight to decrease rehospitalization rates in this

vulnerable patient population.
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CONCEPTUAL/THEORETICAL FRAMEWORK
The Health Belief Model (HBM) emerged from the Public Health Service (early
1950's) orientation toward disease prevention and the problem solving orientation of
social psychologists influenced by Lewinian theory. These scientists were committed to
theory building. Rosenstock (1974) described those earliest Model characteristics
translated from Lewin's valence abstractions. In order for disease avoidance action to be
taken, the individual must perceive susceptibility or subjective risks of contracting a
condition and perceive seriousness or that the condition would create important life

difficulties. These perceptions were thought to provide a force leading to preventive health
action. The particular course of action would be charted by the individual's beliefs. The
"net" beliefs or the perceived benefits of taking action minus the perceived barriers of

taking action would determine the likelihood of taking recommended preventive health
action. "The combined levels of susceptibility and severity provided the energy or force to
act and the perception of benefits (less barriers) provided a preferential path of action"
(Rosenstock, 1974, p.332). Denoted as a modifying factor and less well studied was the
variable described as cues to action (an internal or external instigating event). Other
modifying factors were demographic, sociopsychological and structural variables
(Rosenstock, 1974).
On the basis of literature reviewed for patient acceptance of recommended health
actions, sick role behavior was incorporated into the fabric of the HBM to better predict

likelihood of compliance with prescribed regimens (Becker, 1974; Becker & Maiman,

28

1975). In the sick role, diagnosis of illness has already occurred. The concept of perceived
susceptibility was maintained as patients belief in the diagnosis or its recurrence was found
positively associated with compliance behavior. The presence of (or past experience with)
symptoms affected perceived severity (Becker, 1974).

Becker (1974) stated:
The presence of physical symptoms probably exerts an elevating or "realistic" affect
on perceived severity, motivating the patient to follow the physician's instructions as
long as the organic indications of illness persist (or to avoid their recurrence). Such
behavior would increase the probability of the researcher's obtaining positive
correlations between perceived severity and compliance, at least for the early stages
of treatment (p.413).
Perceived benefits and barriers were maintained as variables associated with likelihood of
prescribed regimen compliance in sick role behavior (Becker, 1974; Becker & Maiman,
1975). Becker and Maiman (1975) outline the "need for research that would attempt to
enhance compliance by modifying the sociobehavioral or other elements proposed in the

Model " (p.21).
Strategies derived from the Health Belief Model suggest methods for accomplishing
patient compliance and other behavior change related to treatment regimens versus
reliance on information sharing or use of professional status as the primary care provider

influencing patient behavior (Elder, Ayala & Harris, 1999). Elder et al. recommend
discovering patients' preconceptions regarding health behavior changes as they relate to
the prevention of illness by assessing patient perceptions of benefit and barrier to engaging
in the health behavior and assessing perceptions of susceptibility and severity of outcome.
These perceptions individualize the health message to be communicated. Discussing how
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to overcome perceived barriers to health behavior and incorporating perceived benefits as
reinforcers of the recommended behavior are strategies derived from the Health Belief

Model which may mediate patient compliance as health behavior change (Elder et al.,
1999).
HYPOTHESES
Two simple, directional hypotheses may be derived from the problem statement : To
what extent do therapeutic regimen compliance beliefs relate to functional limitations in

heart failure patients enrolled in a specialized, outpatient heart failure clinic?
1. There is a positive relationship between patients' functional limitations (designated
by symptom stage/ NYHA Class level) and perceptions of benefit from medication and
dietary compliance (scores on Beliefs about Medication Compliance and Beliefs about

Dietary Compliance Benefits subscales).
2. There is a negative relationship between patients' functional limitations
(designated by symptom stage/NYHA Class level) and perceptions of barriers to
medication and dietary compliance (scores on Beliefs about Medication Compliance and
Beliefs about Dietary Compliance Barriers subscales).

OPERATIONAL DEFINITIONS
An operational definition is "the definition of a concept or variable in terms of the
operations or procedures by which it is to be measured" (Polit and Hungler, 1991, p.650).
New York Heart Association class I-IV designations were used to define participants'

functional limitations. The definitive treatment guidelines which provide practice standards
for heart failure management today utilize NYHA class designations to rank severity of
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functional limitation.These guidelines also support patient self reports as assessment of
functional incapacity. (ACTION HF, 1999; ACC/AHA Task Force, 1995; Konstam et al.,

1994). As previously noted, this classification system has been criticized. These
designations were clarified by the translation of medical jargon into corresponding lay

terminology. Content validity was supported by expert panel review. Physical activities
were more fully described to further simplify and delineate class distinctions (ACC/AHA
Task Force,1995). These clarifications better serve study participants to self describe their
level of functional limitation.

Heart failure patients' beliefs about compliance with medication and dietary regimen
were measured. Participants used a five point scale (from 1=strongly disagree, to
5=strongly agree) to answer questions designed to measure patient perceptions of benefits
and barriers to compliance with a therapeutic regimen. The Beliefs about Medication

Compliance Scale and Beliefs about Dietary Compliance Scale each contain items to
assess perceived benefits and barriers. Participant scores therefore reflected four
subscales: benefits to medication compliance, barriers to medication compliance, benefits
to dietary compliance and barriers to dietary compliance (Bennett et al., 1997).
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CHAPTER III
METHODOLOGY

DESIGN
This is a descriptive correlational study designed to assess compliance beliefs among
select heart failure patients by survey. The subsequent determination of whether or not a

relationship exists between compliance beliefs and functional limitations in heart failure
patients stems from an influencing factor described as a potential limitation in the Beliefs
about Compliance instrument development study of Bennet et al. (1997).
Nonexperimental research was undertaken appropriately here to describe various
characteristics of a select population and to test a theoretical proposition. Designed as a
descriptive correlational study, there is no intention to elucidate cause and effect relations
between the described variables here. A recognized weakness is the potential selection bias

inherent in studying preexisting versus randomly formed groups of heart failure patients.
(Polit and Hungler, 1991).
SAMPLE
Bennett et al. (1997) recruited 61, alert, oriented, English speaking patients with a

medical diagnosis of heart failure from a hospital's specialized outpatient clinic to
participate in the development of an instrument designed to measure beliefs about
compliance with medication and diet. I, the principal investigator, obtained a convenience
sample utilizing the study inclusion criteria of Bennett et al. (1997) by recruiting 61 alert,
oriented English speaking, male and female patients, 18 years of age and older from a
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South Florida outpatient heart failure clinic to participate in the utilization of the
aforementioned authors' tool to assess compliance beliefs. In order to recruit the sample,
the principal investigator was present at the clinic site during regular hours of operation,
two to three days per week for a period of 10 weeks. Most clinic patients' appointments
were scheduled in advance, some were added on and others were seen during regular
hours without appointments as "walk-ins". Patients seen by special appointment outside of
routine clinic hours were not recruited. Participants were recruited by the principal
investigator in the clinic waiting area as they arrived. Patients were excluded from
potential participation if they did not speak English. Patients were also excluded if they
were not on diuretic therapy as the majority of scale items measuring beliefs about

medication compliance refer to taking water pills. Three patients were excluded as nonEnglish speakers over the duration of data collection (2 Hispanic and 1 Haitian, speaking

only Spanish and Creole, respectively).
INSTRUMENTS
a. Demographics
Participants indicated their race, sex, age and New York Heart Association (NYHA)
class level I-IV by operational definition to indicate functional limitations. This
demographic information was obtained in order to assess generalizability of findings,
ascertain study limitations and make meaningful comparisons. The content validity of
NYHA class designations operationalized to allow patient self reporting of functional

limitations was supported by expert panel review.
b. Compliance Beliefs
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Two scales, Beliefs about Medication Compliance and Beliefs about Dietary
Compliance, comprised the tool utilized to assess heart failure patients' beliefs about
therapeutic regimen compliance (Bennett et al., 1997).
Participants used a 5 point Likert scale (=strongly disagree, 2=disagree,

3=undecided, 4=agree and 5=strongly agree) to respond to 24 items designed to measure
perceptions of benefits and barriers to compliance with medication and diet. As

psychosocial scales, the Beliefs about Medication Compliance Scale (BMCS) and the
Beliefs about Dietary Compliance Scale (BDCS) are appropriately evaluated for reliability
in terms of their internal consistency (Munro, 1997). " Internal consistency reliabilities of
the perceived benefits and barriers subscales of the BMCS and BDCS were computed
using Cronbach's alpha statistic" with reported values ranging from 0.68 to 0.91
(Bennett et al., 1997, p.277). A content validity index of 0.81 was determined
and found acceptable. Construct validity of both the BMCS and BDCS was supported by
factor analysis yielding two subscales for each scale; perceived benefits and barriers
( Bennett et al., 1997).

PROCEDURES FOR DATA COLLECTION
Research protocol approval was granted by Florida International University and
following full review, IRB approval was granted by the participating agency. Informed
consent was obtained from all participants by the principal investigator. Clinic patients

were provided a copy of the consent document explaining study purpose, nature of
participation, participant selection, potential risks and benefits, confidentiality pledge and
study contact persons. Having been so informed and after indicating their consent, clinic
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patients responded to questionnaires. The principal investigator administered each
questionnaire at the outpatient heart failure clinic site by reading all items as they appeared

and recording participants responses as indicated by those heart failure patients. The
questionnnaire packets were comprised of the Beliefs about Medication Compliance Scale,
the Beliefs about Dietary Compliance Scale and a page for participants to describe their

demographic characteristics and functional limitations. A five to ten week time frame was
estimated and required to obtain 61 study participants. All completed questionnaires were
secured by the principal investigator and will remain stored in a locked cabinet for a
minimum of three years in the investigator's home.

All study participantswere enrolled in a specialized multidisciplinary heart failure
clinic limiting a potential weakness in design. Bennett et al. (1997) denoted a study

limitation with having 40 % of their participants recruited from private practice settings
and the remaining 61 participants, 60 % of the sample, recruited from a specialized heart

failure clinic. Bennett et al. noted that clinic attendees, by nature of their enrollment, may
be considered to have greater therapeutic regimen knowledge and compliance (1997). In
exploring the relationship between compliance beliefs and functional limitations, a sample
of all clinic attendees may be considered more homogeneous for regimen knowledge and
compliance with regimen versus the dichotomous group recruited for the original
instrument development study of Bennett et al.

METHOD OF DATA ANALYSIS
Study participants were asked to identify their age in years, their race and their level

of functional limitation. Each participant chose the best description of their own
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experience with symptoms. These descriptions of ftunctional limitation, in increasing
severity, were provided in writing, read by the principal investigator and corresponded to
the appropriate New York Heart Association Class level of heart disease. Mean age,
standard deviation and age range in years were calculated. Number and percentage of total
participants were determined by race and New York Heart Association class as did
Bennett et al. (1997).

Participants completed both the Beliefs about Medication Compliance and Beliefs
about Dietary Compliance Scales. To recapitulate, individual item scores ranged from one
to five points. Higher scores indicated increased perception of compliance belief (benefit

or barrier); the participant's increasing agreement with the benefit or barrier item.
Each scale item was coded as a benefit or barrier to compliance as per coding instructions
provided by Dr. Bennett. Scores or participant responses to each benefit and barrier item
were analyzed to determine their frequency distribution across the sample. Total item
agreement by participants is reflected in the combination of positive responses (agree and

strongly agree). Negative responses (strongly disagree and disagree) are combined in
reported findings to reflect total item disagreement by participants.
Benefit and barrier item scores were totaled to obtain four subscale scores per

participant: Benefits ofmedication compliance, barriers to medication compliance,
benefits of dietary compliance and barriers to dietary compliance. Like subscale scores
across the sample were totaled and their sum was divided by 61 (the number of
participants) to obtain a mean score for each aforementioned subscale, respectively. The
means, standard deviations and actual ranges of BMCS and BDCS scores were
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calculated for both the benefits and barriers subscales as did Bennett et al. (1997).
Compliance scale scores and NYHA class designations represent inherently ordinal
data. Spearman's rho was determined designating the magnitude and direction of the

relationship between these two variables (Polit and Hungler, 1991).
The problem statement central to this study formulated as the null hypothesis is:
There is no relationship between compliance beliefs and functional limitations. The chosen
correlation coefficient was further evaluated to accept or reject the null hypothesis. The
critical value for rho, the correlation coefficient and test statistic, (level of significance
=0.05 for a two-tailed test) was compared to the tabeled value. If the absolute value of the
test statistic is greater than the tabled value (tabled value lies between 0.2500 and 0.2732)
then the null hypothesis may be rejected with the conclusion that there is a significant
relationship between beliefs about compliance and functional incapacity (Polit and

Hungler, 1991).
Spearman's rho was calculated using SPSS For Windows to determine the extent of

relationship between a participant's symptom stage (functional limitation) and their
perceived benefits/barriers to therapeutic regimen compliance.
The benefits' subscale scores (benefits of medication and dietary compliance) were
utilized to test hypothesis 1 while each of the barriers' subscale scores (barriers of
medication and dietary compliance) generated per participant were utilized to test

hypothesis 2. Tests of relationship between individual compliance belief items (perceived
benefits and barriers to compliance with medication and diet) and symptom stage
(functional limitation) were also performed.
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PRESENTATION OF FINDINGS
Presented here are the findings of the study conducted with a convenience sample of

61 adult heart failure patients. Data is presented to illuminate sample characteristics,
research questions and hypotheses. The SPSS computer program was used to complete
statistical analysis. Sample characteristics and findings of Bennett et aL.'s 1997
instrument development study are also denoted here for the purpose of discussion and
comparison in Chapter V.

SAMPLE CHARACTERISTICS
The sample (N=61) was comprised of 40 males (65.6%) and 21 females (34.4%).
Data reflects the diversity of the urban outpatient community served in South Florida.
Seven participants were Hispanic (11.5%), 20 participants were White Non Hispanic
(32.8%), 27 participants were Black Non Hispanic (44.3%), 2 participants were Asian
(3.3%) and 5 participants (8.2%) identified their race as other with mixed racial origins in

the East and West Indies.
Sixteen participants (26.2%) identified themselves as asymptomatic with no
limitations to physical activity. This description operationally defines New York Heart
Association (NYHA) Class I, the least severe stage of functional limitation. Thirty

participants (49.2%), the majority of my sample, identified themselves as symptomatic
with moderate physical activity(walking 100 feet on level ground); NYHA Class II. Seven

participants (11.5%) identified themselves as symptomatic with minimal physical activity
(dressing); NYHA Class III. Eight participants (13.1%) identified themselves as
symptomatic with any physical activity or at rest; NYHA Class IV, the most severe stage
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of functional limitation.

Seventy- five percent of my participants combined were identified as having NYHA
Class I and Class II functional limitations versus 25% of my participants combined having
more severe NYHA Class III and IV functional limitations.
Participants ranged in age from 30 to 79 years with a mean age of almost 53 (SD
10.3). The descriptive statistics denoting sample characteristics are displayed in Table
1

.

Relevant comparisons to the findings of Bennett displayed here will be drawn in

Chapter V.
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Table 1 Distribution of sample characteristics by study: gender, race, symptom (sx)
stage and age comparison
Present Study
Frequency
%
Gender:

Male
Female
Total

Bennett Study
Frequency
%

40
21
61

65.6
34.4
100.0

85
16
101

7
20
27
2
5
61

11.5
32.8
44.3
3.3
8.2
100.0

"primarily white"

NYHA Class I
(asymptomatic)

16

26.2

8

8

NYHA Class II

30

49.2

29

29

7

11.5

52

51

13.1

12

12

Race:
Hispanic
White NonHispanic
Black NonHispanic
Asian
Other(E/W Indian)
Total

84
16
100.0

Symptom Stage:

(sx w/ mod. activity*)

NYHA Class III
(sx w/ min. activity**)

NYHA Class IV
(sx w/

any activity/rest)

Age:

Range
Mean
SD

8

35-92
64
11

30-79
52.7
10.3

*symptoms with moderate activity operationally defined as walking 100 feet
**symptoms with minimal activity operationally defined as dressing
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COMPLIANCE BELIEFS
Research question 1: What are the beliefs about medication compliance among heart
failure patients in terms of perceived benefits and perceived barriers?
All 61 study participants completed the 12 item Beliefs about Medication Compliance

Scale (BMCS) comprised of 5 perceived benefit and 7 perceived barrier items. Answers
to this question are derived from responses of heart failure patients to preselected items
pertaining primarily to taking daily diuretics as an integral part of their medication

regimen.
Perceived Benefits of Medication Compliance
To recapitulate, the test items that measured heart failure patients' perceived benefits
to medication compliance are as follows: "When I take my water pills, I do not worry as
much about my heart disease", "IfI take my water pills, I will lower my chance of being
in the hospital", "Taking my water pills lessens my swelling", "Taking my water pills helps

me breathe better" and "Taking my medicine improves my quality of life".
As depicted in Table 2, the greatest benefit of medication compliance as perceived by
heart failure patients is an improved quality of life with 88.5% of the sample indicating

agreement by positive responses to this item. The perceived benefits ranked second and
third (73.7% and 72.2%) regard compliance with diuretics providing decreased chance of
hospitalization and decreased swelling, respectively. The final two benefits items also
addressed compliance with diuretics and were ranked equally with only 45.9% of the
sample indicating item agreement. Less than half of the sample perceived decreased worry

about their heart disease and aid for better breathing from taking their water pills .
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Table 2 Perceived benefits to medication compliance ranked by sample percentage
indicating agreement

1. Taking my medicine improves my quality of life (88.5%)
2.
3.
4.
4.

If I take my water pills, I will lower my chance of being in the hospital (73.7%)
Taking my water pills lessens my swelling (72.2%)
When I take my water pills, I do not worry as much about my heart disease (45.9%)
Taking my water pills helps me breathe better (45.9%)

Table 3 depicts each benefit item and the frequency distribution of responses to that
item. Only 11.5 % of the sample were undecided or disagreed that compliance with

medication improved their quality of life. Overall, benefits to diuretic compliance
specifically, were less strongly perceived. While 26.2% were undecided or disagreed that
taking water pills lessened the chance of hospitalization, 27.8 % were undecided or
disagreed that taking water pills lessened their swelling. A majority of the sample ( 54.1%)
were undecided or disagreed that when they took their water pills, they did not worry as
much about their heart disease. The same percentage of participants (54.1%) were

undecided or disagreed that taking water pills helped them breathe better.
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Table 3 Frequency distribution of the sample according to perceived benefits of
medication compliance (N=61)
Benefit

Frequency

%

Agree /strongly agree
Undecided
Strongly disagree/disagree
Total

54
4
3
61

88.5
6.6
4.9
100.0

If I take my water pills, I will lower my chance
of being in the hospital
Agree/strongly agree

45

73.7

Undecided

15

24.6

Taking my medicine improves my quality of life

Strongly disagree/disagree

Total

1

1.6

61

100.0

Taking my water pills lessens my swelling
Agree/strongly agree

44

72.2

Undecided
Strongly disagree/disagree
Total

11
6
61

18.0
9.8
100.0

28
21

45.9
34.4

When I take my water pills, I do not worry
as much about my heart disease

Agree/Strongly agree
Undecided
Strongly disagree/disagree

12

19.7

Total

61

100.0

Taking my water pills helps me breathe better
Agree/strongly agree

28

45.9

Undecided

22

36.1

Strongly disagree/disagree

11

18.0

Total

61

100.0

Perceived Barriers to Medication Compliance
To recapitulate, the test items that measured heart failure patients' perceived barriers
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to medication compliance are the following: "Taking water pills is hard to remember",
"Taking water pills is unpleasant", "I have to take too many water pills each day", "Taking
water pills makes it hard for me to go away from home", "I forget to take my water

pills", "Taking water pills makes me worry about my heart disease" and "Taking water
pills wakes me up at night to go to the bathroom". As depicted in Table 4, the greatest

barrier to medication compliance, specifically, taking diuretics, as perceived by heart
failure patients is being made to wake up at night to go to the bathroom. Diffliculty going
away from home ranked second as a perceived barrier to diuretic compliance among the
sample. While 18.1% of the sample perceived taking water pills as unpleasant, 14.8%
agreed to forgetting to take their water pills as a barrier to compliance. The three lowest
ranking barriers to diuretic compliance as perceived by the sample were: " Taking water
pills is hard to remember" with 9.8% indicating item agreement, "Taking water pills makes
me worry about my heart disease" with 4.9% indicating item agreement and "I have to
take too many water pills each day" with only 3.2% indicating item agreement.

Table 4 Perceived barriers to medication compliance ranked by sample percentage
indicating agreement.

1.
2.
3.
4.

Taking water pills makes me wake up at night to go to the bathroom (52.5%)
Taking water pills makes it hard for me to go away from home (24.6%)
Taking water pills is unpleasant (18.1%)
I forget to take my water pills (14.8%)

5. Taking water pills is hard to remember (9.8%)
6. Taking water pills makes me worry about my heart disease (4.9%)
7. I have to take too many water pills each day (3.2%)

Table 5 depicts each barrier item and the frequency of responses to that item. Overall,
these items were not strongly perceived as barriers to compliance with diuretic therapy by

44

the heart f

e patients in this sample. While 52.5% of the sample perceived being made

to wake up at night to go to the bathroom as a barrier to taking water pills, the remaining
47.5% therefore, were undecided or disagreed with the item. Almost 76% of these heart

failure patients were undecided or disagreed that taking water pills made it hard for them
to go away from home while almost 82% were undecided or disagreed that taking water
pills is unpleasant. Slightly greater than 85% of the sample expressed indecision or
disagreement with the item "I forget to take my water pills". Similarly, slightly greater
than 90% were undecided or disagreed that "Taking water pills is hard to remember".
Greater still were the percentages of the sample undecided or that disagreed with items

"Taking water pills makes me worry about my heart disease" and "I have to take too many
water pils each day".
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Table S Frequency distribution of sample by perceived barriers to medication
compliance (N=61)
Barriers

Frequency

Taking water pills wakes me up at night to
go to the bathroom
Agree/strongly agree

Undecided

%

32

52.5

8

13.1

Strongly disagree/disagree

21

34.4

Total

61

100.0

Agree/strongly agree
Undecided

15
8

24.6
13.1

Strongly disagree/disagree

38

62.3

Total
Taking water pills is unpleasant
Agree/strongly agree
Undecided

61

100.0

11
7

18.1
11.4

Taking water pills makes it hard for me to go
away from home

Strongly disagree/disagree

43

70.5

Total

61

100.0

9

14.8

7
45
61

11.5
73.7
100.0

6
7
48
61

9.8
11.5
78.7
100.0

3
8

4.9
13.1

50
61

82.0
100.0

I forget to take my water pills
Agree/strongly agree

Undecided
Strongly disagree/disagree
Total
Taking water pills is hard to remember

Agree/strongly agree
Undecided
Strongly disagree/disagree
Total
Taking water pills makes me worry about
my heart disease

Agree/strongly agree
Undecided
Strongly disagree/disagree
Total
I have to take too many water pills each day
Agree/strongly agree

Undecided
Strongly disagree/disagree
Total
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2

3.2

9

14.8

50
61

82.0
100.0

Research question 2: What are beliefs about dietary compliance among heart failure
patients in terms of perceived benefits and perceived barriers?
All 61 study participants completed the 12 item Beliefs about Dietary Compliance
Scale (BDCS) comprised of 6 perceived benefits and 6 perceived barriers to compliance
with recommended diet. Answers to this question are derived from responses of heart
failure patients to preselected items pertaining to following a low sodium diet; a

therapeutic intervention central to prudent heart failure management.
Perceived Benefits of Dietary Compliance

To recapitulate, the test items that measured heart failure patients' perceived benefits
to dietary compliance are the following: " Eating a low salt diet will keep me healthy",
"Eating a low salt diet will keep my heart healthy", "Eating a low salt diet will keep my
swelling down", "Eating a low salt diet will keep fluid from building up in my body",

"When I follow my low salt diet, I feel better" and "Eating a low salt diet will help me
breathe easier". As depicted in Table 6, the greatest benefit of dietary compliance as
perceived by heart failure patients is keeping the heart healthy (96.7%) followed closely
the perception that eating a low salt diet will maintain general health (95.1%). Also closely
paired by rank as perceived benefits of eating a low salt diet are keeping fluid build up and
swelling down (91.85 and 90.2%, respectively). Eighty-two percent of the sample cites
feeling better when low sodium compliant while only 59% perceive easier breathing as a
benefit of eating a low salt diet.
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Table 6 Perceived benefits to dietary compliance ranked by sample percentage

indicating agreement
1.Eating a low salt diet will keep my heart healthy (96.7%)
2.Eating a low salt diet will keep me healthy (95.1%)
3.Eating a low salt diet will keep fluid from building up in my body (91.8%)
4.Eating a low salt diet will keep my swelling down (90.2%)
5.When I follow my low salt diet, I feel better (82%)
6.Eating a low salt diet will help me breathe easier (59%)

Table 7 depicts each benefit item and the frequency of responses to that item.
Overall, these items were strongly perceived as benefits to compliance with a low salt diet.

An exception across this sample of heart failure patients was the item "Eating a low salt
diet will help me breathe easier". Forty one percent of participants were undecided or
disagreed that diet compliance would ease their breathing.
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Table 7 Frequency distribution of sample by perceived benefits of dietary
compliance (N=61)
Frequency

Benefits

%

Eating a low salt diet will keep my heart

healthy
Agree/strongly agree

59

96.7

Undecided
Strongly disagree/disagree
Total

2
0
61

3.3
0
100.0

Eating a low salt diet will keep me healthy
Agree/strongly agree

58

95.1

2

3.3

Undecided

1

Strongly disagree/disagree

Total

1.6

61

100.0

56
4

91.8
6.6

Eating a low salt diet will keep fluid

from building up in my body
Agree/strongly agree
Undecided

1

1.6

Total

61

100.0

Eating a low salt diet will keep my
swelling down
Agree/strongly agree

55

90.2

Undecided

3

4.9

Strongly disagree/disagree

3

4.9

61

100.0

50
4
7
61

82.0
6.6
11.4
100.0

36
19
6
61

59.0
31.2
9.8
100.0

Strongly disagree/disagree

Total
When I follow my low salt diet, I feel better
Agree/strongly agree
Undecided
Strongly disagree/disagree
Total
Eating a low salt diet will help me breathe easier

Agree/strongly agree
Undecided
Strongly disagree/disagree
Total

Perceived Barriers tDietar Complane
To recapitulate, the test items that measured heart failure patients' perceived barriers
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to dietary compliance are as follows: "Salty food is not good for me", "I cannot go out to
many places to eat because of the low salt diet", "Food does not taste good on the low
salt diet", "Following a low salt diet costs too much money", "Following a low salt diet

takes too much time" and "Following a low salt diet is too hard to understand". As
depicted in Table 8, the greatest barrier to dietary compliance as perceived by heart failure
patients is that salty food is not good for them. The remaining items were not strongly
perceived barriers to dietary compliance across this sample. Less than half of the sample
agreed that they could not go out to many places to eat because of dietary sodium
restriction (49.2%) and that food didn't tast good on the diet (45.9%). Even fewer
participants agreed that cost (24.6%), complexity (16.4%) and time (14.7%) were diet

compliance barriers.
Table 8 Perceived barriers to dietary compliance ranked by sample percentage
indicating
agreement
1.
2.
3.
4.
5.
6.

Salty food is not good for me (95.1%)
I cannot go out to many places to eat because of the low salt diet (49.2%)
Food does not taste good on the low salt diet (45.9%)
Following a low salt diet costs too much money (24.6%)
Following a low salt diet is too hard to understand (16.4%)
Following a low salt diet takes too much time (14.7%)

Table 9 depicts each barrier item and the frequency of responses to that item. Overall,
these items were weakly perceived as barriers to dietary compliance with the exception of
"Salty food is not good for me" to which greater than 95% of this sample indicated
agreement. A majority of the sample was undecided or disagreed with the remaining
barriers to dietary compliance: "I cannot go out to many places to eat because of the low
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salt diet" (50.8%), "Food does not taste good on the low salt diet" (54.1%), "Following a
low salt diet costs too much money" (75.4%), "Following a low salt diet is too hard to
understand" (83.6%), and "Following a low salt diet takes too much time

"

(85.3%).

Frequency distribution of sample by perceived barriers to dietary
compliance (N=61)
Barriers
Frequency
%
T

Salty food not good for me
Agree/strongly agree

Undecided
Strongly disagree/disagree

58

95.1

2

3.3

1

1.6

Total

61

100.0

I cannot go out to many places to eat
because of the low salt diet
Agree/strongly agree

30

49.2

5

8.2

Undecided
Strongly disagree/disagree

26

42.6

Total

61

100.0

Food does not taste good on the low salt diet
Agree/strongly agree

28

45.9

1

1.6

Strongly disagree/disagree

32

52.5

Total

61

100.0

15
0

24.6
0
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Strongly disagree/disagree
61
Total
Following a low salt diet is too hard to understand
10
Agree/strongly agree

75.4
100.0

1
50
61

1.6
82.0
100.0

9
2

14.7
3.3

50
61

82.0
100.0

Undecided

Following a low salt diet costs too much money

Agree/strongly agree
Undecided

Undecided
Strongly disagree/disagree
Total

16.4

Following a low salt diet takes too much time

Agree/strongly agree
Undecided
Strongly disagree/disagree
Total

Table 10 denotes heart failure patients' beliefs about therapeutic regimen
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compliance by perceived benefit/perceived barrier subscale mean score. Bennett's findings
are denoted here for the purpose of later discussion and comparison. Higher scores again

indicate increased participant perception of respective benefit or barrier to compliance.
The possible total score range for each of the subscales, benefits to medication compliance
and barriers to medication compliance, are 5 to 25 and 7 to 35, respectively. . The mean
score for participant perceived benefit to medication compliance was 18.57 (SD 2.56)
with an actual range in benefit subscale scores of 14 to 25. The mean score for participant
perceived barriers to medication compliance was 16.75 (SD 3.33) with an actual range in
barrier subscale scores of 11 to 28.
The total, possible benefit or barrier subscale score range for the Beliefs about
Dietary Compliance Scale was 6 to 30 , respectively. Actual scores for perceived benefits
to dietary compliance ranged from 17 to 28 (mean=23.74, SD=2.29) with scores for
perceived barriers on this subscale ranging from 11 to 26 (mean=17.10, SD=3.23).
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Table 10 Descriptive data for study comparison: Compliance benefit and barrier
mean scores and ranges
Present Study
Scores

N

No.
items

Mean

SD

Actual
Range

Possible
Range

Beliefs/Medication

Compliance
Benefits Subscale
Barriers Subscale

61
61

5
7

18.57
16.75

2.56
3.33

14-25
11-28

5-25
7-35

Beliefs/Diet
Compliance
Benefits Subscale
Barriers Subscale

61
61

6
6

23.74
17.10

2.29
3.23

17-28
11-26

6-30
6-30

Bennett Study
Scores

N

No.
items

Mean

SD

Actual
Range

Possible
Range

Beliefs/Medication
Compliance
Benefits Subscale
Barriers Subscale

98
98

5
6

19.84
13.07

3.84
3.44

10-25
6-24

5-25
6-30

Beliefs/Diet
Compliance
Benefits Subscale
Barriers Subscale

101
101

7
5

29.08
12.70

4.34
4.00

17-35
5-23

7-35
5-25

FUNCTIONAL LIMITATIONS
Research question 3: What are the functional limitations among heart failure patients?
Functional limitations or symptom stages among heart failure patients are defined as
increasingly severe from NYHA (New York Heart Association) Class I to Class IV.
NYHA four tier classification system defining functional limitation is described below
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with the corresponding underlined description provided to study participants (in writing
and as read by the principal investigator to the participant in administration of each
survey) for self report of functional limitations.
NYHA Class I-Cardiac disease without resulting limitations of physical activity.
I have been told I have heart failure but it does not limit my physical activity

NYHA Class Il-Slight limitation of physical activity--comfortable at rest, but ordinary
physical activity results in fatigue, palpitation, dyspnea, or anginal pain. I am comfortable
at rest but walking 100 feet on level ground makes me feel: tired, short of breath, like
my heart beats too fast, like my heart beats irregularly, pressurere in my chest, pain in my
chest, tightness in my chest.
NYHA Class Ill-Marked limitation in physical activity--Comfortable at rest, but less than
ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain. I am
comfortable at rest but getting dressed makes me feel: tired, short of breath, like my heart

beats too fast, lie m he

beats rregularlypressure

in my chest, pain in my chest,

tightness in my chest.

NYHA Class IV-Inability to carry on any physical activity without discomfort or
symptoms at rest. Any physical activity makes me feel: tired, short o breath like

y

heart beats too fast, like my heart beats irregularly, pressure in my chest, pain in my chest,
tightness

my chest.

The sample was previously characterized by functional limitation and is so described in
Table 1.
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RELATIONSHIPS BETWEEN COMPLIANCE BELIEFS AND FUNCTIONAL
LIMITATIONS
Hypothesis 1: There is a positive relationship between patients' functional limitations
(designated by symptom stage/NYHA Class level) and perceptions of benefit from

medication and dietary compliance (scores on Beliefs about Medication Compliance and
Beliefs about Dietary Compliance Benefits subscales).
To recapitulate, a nonparametric test of correlation was applied between participants'
functional limitations and each benefit subscale score (benefits of dietary and medication
compliance) to test this hypothesis. The hypothesis is supported, strongly by a statistically

significant positive relationship demonstrated between functional limitations and perceived
benefits to medication compliance and with a "near" statistically significant positive

relationship between functional limitations and perceived benefits to dietary compliance
(p=0.053) (See Table 11).Participant's symptom stage (functional limitation) positively
correlated with Beliefs about Medication Compliance/total benefits subscale scores
(Spearman's rho=0.345, p=0.007, level of significance is .01) and came close to a

statistically significant positive correlation with Beliefs about Dietary Compliance/total
benefits subscale scores (Spearman's rho=0.249, p=0.53, level of significance is .05).

It is concluded that there is a positive relationship between patients' functional limitations
and perceptions of benefit from medication and dietary compliance (See Table 11).

Hypothesis 2: There is a negative relationship between patients' functional limitations
(designated by symptom stage/NYHA Class level) and perceptions of barriers to

medication and dietary compliance (scores on Beliefs about Medication Compliance and
Beliefs about Dietary Compliance Barriers subscales).
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Again, nonparametric testing was applied between participants' reported functional
limitations and each barriers to medication/dietary compliance subscale score. This

hypothesis was supported, in part only ; a statistically significant correlation between
functional limitations and perceived barriers to medication compliance was demonstrated.
No significant relationship between functional limitations and perceived barriers to dietary
compliance was found. A statistically significant negative correlation was found between
participants' symptom stage(finctional level) and Beliefs about Medication Compliance/
total barriers subscale scores (Spearman's rho= -0.310, p=0.015, level of significance is
.05) while symptom stage and Beliefs about Dietary Compliance/total barriers subscale
scores were not found to correlate with statistical significance here.
It is concluded that there is a negative relationship between patients' functional limitations
and perceptions of barrier to medication compliance (See Table 11).
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Table 11

Correlations between functional limitations (symptom stage) and
therapeutic regimen compliance beliefs (subscale mean scores)
Medication Compliance

Diet Compliance

Beliefs
barriers

Symptom
stage

Beliefs
barriers
benefits

1.000

0.345
.007**

-0.310
.015*

0.249
.053

-0.030
.817

1.000

-0.264
.040*

0.382
.002**

-0.035
.788

-0.264
.040*

1.000

0.007
.959

0.279
.029*

rho 0.249
p .053

0.382

0.007
.959

1.000

rho -0.030
p .817

-0.035
.788

Symptom rho
stage
p

benefits

Medication Compliance
Beliefs
benefits

rho 0.345
p .007**

barriers

rho -0.310
p .015*

Diet Compliance
Beliefs
benefits

barriers

.002**

0.278
.029*

-0.177
.172

-0.177
.172
1.000

*p=05 significant

**p=.1 highly significant
Additional relationships emerged from data analysis. Beliefs about Medication
Compliance/ total benefits subscale scores negatively correlated with Beliefs about
Medication Compliance/ total barriers subscale scores (Spearman' s rho= -0.264, p=0.040,
level of significance is .05) and positively correlated with Beliefs about Dietary
Compliance/ total benefits subscale scores (Spear

's rho=0.382, p=0.002, level of

significance is .0 1). Beliefs about Medication Compliance/ total barriers subscale scores
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positively correlated with Beliefs about Dietary Compliance/ total barriers subscale scores
(Spearman's rho= 0.279, p=0.0 2 9 , level of significance is .05). No other correlations
between therapeutic regimen compliance beliefs benefits/barriers subscale scores were

found statistically significant (See Table 11).
Research question 4: What is the relationship between functional limitations and beliefs
about medication and dietary compliance in terms of perceived benefits and barriers?
The relationships between

ctional

limitation and individual benefit and

barrier items on both Compliance Scales (Medication and Dietary) were measured (See
Tables 12, 14, 16, and 18). All testing was two-tailed. Additionally, correlations between
belief items in each subscale were demonstrated and are depicted in Tables 13, 15, 17 and

19, respectively.
Five items on the Beliefs about Medication Compliance Scale are coded as perceived
benefits to medication compliance and two of these individual items ( "IfI take my water
pills I will lower my chance of being in the hospital"--Spearman's rho=0.477, p=.OO,
level of significance= .001 and "Taking my water pills lessens my swelling"--Spearman's
rho=0.394, p=.002, level of significance=.01) positively correlate with functional

limitation.
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Table 12 Correlations between functional limitation (symptom stage) and
perceived benefits of medication compliance

Symptom

BMCS perceived benefits
#3

#2

Stage

#1

rho
p

1.000

0.062
.635

rho
p

0.062
.635

1.000

#2

rho
p

0.477
.000*

0.287
1.000
.025 *

#3

rho
p

0.394
.002**

0.096
.462

#4

rho
p

0.120
.357

#5

rho
p

0.189
.145

0.014
.913

BMCS

Beliefs about Medication Compliance Scale

Symptom
Stage
BMCS
Benefits
#1

#4

0.120
0.394
0.477
.000*** .002**
.357

0.287
.025*

#5

0.189
.145

0.096
.462

0.280
.029*

0.014
.913

0.356
.005*

0.345
.006*

0.256
.046*

0.302
.018*

0.258
.045*

0.302
0.280 0.345
.029* .006** .018*

1.000

0.225
.081

0.256
.046*

0.225
.081

1.000

0.356
1.000
.005**

0.258
.045*

Benefits
# 1 When I take my water pills, I do not worry as much about my heart disease
#2 If I take my water pills, I will lower my chance of being in the hospital

# 3 Taking my water pills lessens my swelling
# 4 Taking my water pills helps me breathe better

# 5 Taking my Medicine improves my quality of life
*

**

p=.05 significant
p=.O1 highly significant

***p=.001 very highly significant

Tests of correlation also revealed 7 statistically significant relationships between benefit

items as depicted in Table 13.
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Table 13 Correlations between perceived benefits of medication compliance
"When I take my water pills, I don't worry as much about my heart disease" correlates

with:
"If I take my water pills, I will lower my chance of being in the hospital"
"Taking my water pills helps me breathe better"
"If I take my water pills I will lower my chance of being in the hospital"

correlates with:
"Taking my water pills lessens my swelling"
"Taking my water pills helps me breathe better"
"Taking my medicine improves my quality of life"
"Taking my water pills lessens my swelling"

correlates with:
"Taking my water pills helps me breathe better"
"Taking my medicine improves my quality of life"

Seven items are coded as perceived barriers on the Beliefs about Medication
Compliance Scale and 4 of these demonstrate statistically significant negative correlations
with fimctional limitation ("Taking water pills is hard to remember"--Spearman's rho=
-0.305, p=.017, level of significance =.05, "I have to take too many water pills each
day"--Spearman's rho=-.0513, p=.000, level of significance=.001, " I forget to take my

water pills"--Spearman's rho=-0.302, p=.018, level of significance=.05, and "Taking water
pills makes me worry about my heart disease"--Spearman's rho=-0.290, p=.023, level of
significance=.05).
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Table 14 Correlations between functional limitation (symptom stage) and
perceived barriers to medication compliance
Symptom BMCS perceived barriers
#4
#3
#2
#1
Stage

Symptom
Stage
BMCS
Barriers
#1

#2

rho 1.000
p

#6

#7

-0.305 -0.209 -0.513 -0.065 -0.302 -0.290
.017* .106
.000*
.619
.018* .023*

0.237
.065

rho -0.305
.017*
p

1.000 0.411 0.405 0.198
.001*** .001*** .125

rho -0.209
p
.106

0.411

0.320 0.129
.012* .323

1.000

.001***

0.578

0.526

0.033

.000***.000*** .802

0.315 0.229
.013* .076

-0.165
.204

1.000

0.237 0.328 0.419 -0.184
.066 .010** .001*** .157

0.237
.066

1.000

0.244
.058

0.250
.052

0.073
.576

0.578 0.315 0.328 0.244
.010** .058
,000*** .013*

1.000

0.640

-0.270

0.405 0.320

rho -0.513
p
.
***

.001*** .012*

#4

rho -0.065
p
.619

0.198 0.129
.125 .323

#5

rho -0.302
.018*
p

#3

#5

.000*** .036*

0.419 0.250 0.640 1.000
.001*** .052 .000***

-0.191
.141

0.073 -0.270 -0.191
.036* .141
.576

1.000

#6

rho
p

-0.290
.023*

0.526 0.229
.000*** .076

#7

rho
p

0.237
.065

0.033 -0.165 -0.184
.157
.802 .204

BMCS Beliefs about Medication Compliance Scale
Barriers
#1 Taking water pills is hard to remember
#2 Taking water pills is unpleasant
#3 I have to take too many water pills each day
#4 Taking water pills makes it hard for me to go away from home
#5 I forget to take my water pills
#6 Taking water pills makes me worry about my heart disease
#7 Taking water pills wakes me up at night to go to the bathroom(*p=.05
significant,* *p=.01 highly significant,** *p=.001 very highly significant)
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Statistically significant relationships between barrier items are also revealed with tests of
correlation as depicted in Table 15.
Table15 Correlations between perceived barriers to medication compliance

"Taking water pills is hard to remember"
correlates with:
"Taking water pills is unpleasant"
"I have to take too many water pills each day"
"I forget to take my water pills"
"Taking water pills makes me worry about my heart disease"
"Taking water pills is unpleasant"

correlates with:
"I have to take too many water pills each day"
"I forget to take my water pills"
"I have to take too many water pills each day"

correlates with:
"I forget to take my water pills"

"Taking water pills makes me worry about my heart disease"
"I forget to take my water pills"

correlates with:
"Taking water pills makes me worry about my heart disease"
"Taking water pills wakes me up at night to go to go to the bathroom"

Six items on the Beliefs about Dietary Compliance Scale are coded as perceived
benefits to dietary compliance; one of these individual items correlates strongly with
functional limitation ("Eating a low salt diet will keep me healthy"-Spearman' s
rho=0.275, p=.032, level of significance =.05). A second subscale item ("Eating a low salt
diet will keep my heart healthy"--Spearman's rho=0.234, p=.070) correlates marginally
with functional limitation.
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Table 16 Correlations between functional limitation (symptom stage) and
perceived benefits to dietary compliance
Symptom

BDCS perceived benefits

Stage

#1

#2

#3

#4

#5

1.000

0.275 0.234
.032*
.070

0.210
.104

0.118
.366

0.011
.933

rho
p

0.275
.032*

1.000

0.658

0.388

0.052

.02**

.691

#2

rho
p

0.234
.070

0.660 1.000
.000***

0.515
0.405
0.054
.000*** .001*** .680

#3

rho
p

0.210
.104

0.658

1.000

Symptom
Stage
BDCS
Benefits
#1

#4

rho
p

.000

rho
p

0.118
.366

#5

rho
p

0.011
.933

0.052
.691

#6

rho
p

0.199

0.128

.124

.325

0.660
.000***

0.515
***

.000***

0.388 0.405
.002** .001***

#6

0.199
.124

0.128
.325
0.189
.144

0.560

0.093 0.127
.000*** .478 .330

0.580
1.000
.000***

0.111 0.230

.394

.074

0.054
.680

0.093
.478

0.111
.394

1.000

0.388
.002**

0.189
.144

0.127
.330

0.230
.074

BDCS Beliefs about Dietary Compliance Scale
Benefits
#1 Eating a low salt diet will keep me healthy
#2 Eating a low salt diet will keep my heart healthy
#3 Eating a low salt diet will keep my swelling down
#4 Eating a low salt diet will keep fluid from building up in my body
#5 When I follow my low salt diet, I feel better
#6 Eating a low salt diet will help me breathe easier
*p=.05 significant
**p0=. 1 highly significant
*** p=.001 very highly significant

63

0.388 1.000
.002**

Additionally, statistically significant relationships are demonstrated between benefit items
of the Beliefs about Dietary Compliance Scale (See Table 17).

T-able 17

"Eating

Correlations between perceived benefits of dietary compliance

low salt diet wil keep me healthy"
correlates with:
a

"Eating a low salt diet will keep my heart healthy"
"Eating a low salt diet will keep my swelling down"
"Eating a low salt diet will keep fluid from building up in my body"
"Eating a low salt diet will keep my heart healthy"

correlates with:
"Eating a low salt diet will keep my swelling down"
"Eating a low salt diet will keep fluid from building up in my body"
"Eating a low salt diet will keep my swelling down"

correlates with:
"Eating a low salt diet will keep fluid from building up in my body"
"When I follow my low salt diet, I feel better"

correlates with:
"Eating a low salt diet will help me breathe easier"

Of the six items on the Beliefs about Dietary Compliance Scale coded as perceived
barriers to dietary compliance, only one of these individual items correlates significantly
with functional limitation ("Salty food is not good for me"--Spearman's rho=.348**,
p=.OO6, level of significance=.01). A few significant relationships between barrier items to
dietary compliance were also revealed (See Tables 18 and 19).
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Table 18

Symptom
Stage
BDCS
Barriers
#1

Correlations between functional limitation (symptom stage) and
perceived barriers to dietary compliance

rho
p

Symptom

BDCS perceived barriers

Stage

#1

1.000

#2

0.348 -0.015
.006** .906

#3

-0.016
.902

#4

-0.123
.345

#5

-0.142
.275

#6

-0.057
.662

rho
p

0.348

1.000

-0.126
.332

#2

rho
p

-0.015 -0.126
.332
.906

1.000

0.227
.078

#3

rho
p

-0.016 -0.271
.902
.035*

0.227
.078

1.000

#4

rho
p

-0.123 -0.057
.345
.665

0.221
.087

0.330
1.000
.009**

0.557
0.378
.000*** .003**

#5

rho
p

-0.142 -0.130
.275
.318

0.161
.214

0.077
.558

0.557
000***

1.000

0.248
.054

#6

rho
p

-0.057 -0.101
.662 .440

0.219
.090

0.251
.051

0.378

0.248
.054

1.000

.006**

-0.271
-0.057
.035 * .665

-0.130
.318

-0.101
.440

0.221
.087

0.161
.214

0.219
.090

0.330

0.077
.558

0.251
.051

.009**

.003**

BDCS Beliefs about Dietary Compliance Scale
Barriers
#1
#2
#3
#4
#5
#6

Salty food is not good for me
I cannot go out to many places to eat because of the low salt diet
Food does not tast good on the low salt diet
Following a low salt diet costs too much money
Following a low salt diet takes too much time
Following a low salt diet is too hard to understand

*p=.05 significant
**p=.01 highly significant

*p=.001 very highly significant
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Table 19

Correlations between perceived barriers to dietary compliance

"Salty food is not good for me"
correlates with:
"Food does not taste good on the low salt diet"
"Food does not tast good on the low salt diet"
correlates with:
"Following a low salt diet costs too much money"
"Following a low salt diet costs too much money"

correlates with:
"Following a low salt diet takes too much time"
"Following a low salt diet is too hard to understand"
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CHAPTER V
DISCUSSION
DISCUSSION AND COMPARISONS
This chapter discusses study findings and compares relevant findings to Bennett et
al's 1997 instrument development study. Nursing implications, study limitations and
recommendations for further nursing study are herein noted.
To recapitulate, the purpose of this study was to determine the extent of relationship

between heart failure patients beliefs about compliance with therapeutic regimen and their
functional limitations. To that end, patients at a specialized outpatient clinic in South
Florida were recruited by meeting the inclusion criteria of Bennett's study. Participants

were asked to report their functional limitations indicating presence of or experience with
symptoms ( Health Belief Model variable of perceived susceptibility/severity). Participants
were also asked to indicate their response to scale items derived by Bennett et al. from the
Health Belief Model (HBM) to measure beliefs about compliance with medication and diet
( variables of perceived benefits and perceived barriers to recommended health actions).

The Health Belief Model (Becker, 1974) and the Bennett investigators suggest that heart
failure patients' compliance beliefs may differ according to their classification level of
disease. The findings of this study lend support to that suggestion.
In a review of published research regarding compliance with therapeutic

regimen, Sacket and Haynes (1976) found that symptomatic patients showed higher
compliance rates, regardless of the method by which compliance with therapeutic regimen
was operationalized. As previously noted, perceived benefits and barriers were maintained
as variables associated with the likelihood of prescribed regimen compliance in sick role
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behavior as per Becker and Becker & Maiman studies of the mid 1970's. Maiman, Becker,
Kirscht, Haefher and Drachman (1977) applied the HBM to chronic illness behavior in a
study of long term therapeutic regimen compliance as diet modification and found that

individual's compliance behaviors correlated with measured health beliefs. Can an
assessment of compliance beliefs and what relates to them, as undertaken in the present
study, provide some predictive value for the health care provider as to likelihood of
patient following recommended health action or perhaps, the converse is true? Sackett

and Haynes (1976) found some evidence to suggest that compliance behavior changes
precede health belief changes. The Health Belief Model and those findings underscored
above provide the theoretic underpinnings for this work.
Compliance Beliefs
Compliance beliefs of heart failure patients were measured using Bennett et al's
instruments developed for this purpose. As compared to Bennett's sample,the present
sample was smaller in size, more culturally diverse, less functionally limited and slightly

younger. Males also comprised the majority of participants (N=101) in the Bennett study
described therein racially, as primarily White. The majority of participants in the present
study had a lesser degree of functional limitation than the majority of participants in
Bennett et al.'s study. Conversely, 37% of Bennett et al's study participants combined
were identified as having NYHA Class I and Class II limitations while 63% of their
participants combined, the majority, were identified as having more severe functional
limitations; NYHA Class III and Class IV. Bennett's sample reflected a slightly broader

age range and older participant by mean age than the present study. These attributes may
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or may not be relevant in the comparison of our study findings. With a larger sample
size (N=98 versus 61) and slightly broader actual range of scores, Bennett's mean
perceived benefit to medication compliance subscale score, for example (mean=19.84,
SD=3.84 ) is slightly higher than that of the present study. Bennett's mean perceived
barrier to medication compliance subscale score (meanl13.07, SD=3.44 ) is slightly lower
as compared to the corresponding mean barrier subscale score obtained in the present
study. Bennett's original instrument development study (1997) identified 7 items as

perceived benefits to dietary compliance and 5 items as perceived barriers, two subscales
of the Beliefs about Dietary Compliance Scale, completed by 101 participants. Mean
subscale scores are relevant in context of comparison to Bennett's with perceived benefits
to diet compliance greater and perceived barriers to diet compliance less than those mean
subscale scores in this study . Bennett's mean perceived benefit subscale score
(mean=29.08, SD=4.34, possible range 7 to 35) was again higher than that of the present
study. Similarly, Bennett's mean perceived barriers to dietary compliance subscale score
(mean=12.70, SD=4.00, possible range 5 to 25) as compared to the corresponding mean
score obtained in the present study, was again lower. Actual ranges of subscale scores for
participant perceived benefits of and barriers to dietary compliance are 17 to 35 and 5 to
23, respectively; slighter broader than for my smaller sample. It is undetermined whether
or not the greater perceived benefits to therapeutic regimen compliance by mean score and
the lesser perceived barriers to therapeutic regimen by mean score are statistically
significant in their difference to the present study.
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The item most highly perceived as a benefit to medication compliance in this sample is
improved quality of life with lower chances of being hospitalized and less swelling

subsequently identified in rank order as perceived benefits, respectively. All three items,
thereby may be considered of clinical significance for this sample. The benefit item ranked
most highly ("Taking my medicine improves my quality of life") did not correlate with
functional limitation. This lack of correlation may suggest that the benefit is perceived so
greatly as to apply to all heart failure patients, superseding symptom level. It is also,

notably, the only generic versus diuretic medication compliance item measured here.
Items coded as benefits to medication compliance and found equivocal as perceived
by this sample group were decreased worry about heart disease and better breathing.
These items may be labeled as equivocal benefits since participants' negative and
undecided responses to them closely rivaled their item agreement. It may be important to
recall that the majority of the sample self identified as NYHA Class I and II and therefore
were perhaps better compensated with less worry where difficulty breathing was not a
primary manifestation of their heart failure. It is also possible that this sample is just less
representative of pulmonary congestive features.

Diuretic therapy was the primary theme of the Beliefs about Medication Compliance
Scale. Number of pills to be taken, complexity of regimen and access to pharmacy
services have been cited in the compliance literature as previously noted and by this
sample group, in informal discussion during data collection, as barriers to compliance with

medication regimen.
The majority of participants in this sample did not perceive the items below
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as great barriers to medication compliance, primarily compliance with diuretic therapy, as
previously noted, with the exception of "Taking water pills wakes me up at night to go to
the bathroom" to which a majority of participants responded positively.
1. Taking water pills makes me wake up at night to go to the bathroom (52.5%)
2. Taking water pills makes it hard for me to go away from home (24.6%)
3. Taking water pills is unpleasant (18.1%)
4. I forget to take my water pills (14.8%)
5. Taking water pills is hard to remember (9.8%)
6. Taking water pills makes me worry about my heart disease (4.9%)

Perhaps, heart failure patients managed in a specialized outpatient clinic may be more
compliant as a group perceiving less barrier to the traditional negatives associated with
diuretic therapy or these preselected items centering on diuretic therapy do not adequately
reflect the barriers to medication compliance perceived in this group.

Overall, benefits to dietary compliance were strongly perceived by this sample with
the exception of a low salt diet perceived not as strongly as a preventive of breathing
difficulty. Again, with the majority of patients less symptomatic and/or better

compensated, perhaps pulmonary congestion/respiratory manifestations are not prevalent.
Though patients perceived the low salt diet as means to prevent fluid buildup they may not

extend that concept to lung physiology.
Of 6 compliance with diet subscale items, only one ( "Salty food is not good for me") was
perceived strongly as a compliance barrier with a large percentage of participants
indicating agreement to the item.
1.
2.
3.
4.
5.

Salty food is not good for me (95.1%)
I cannot go out to many places to eat because of the low salt diet (49.2%)
Food does not taste good on the low salt diet (45.9%)
Following a low salt diet costs too much money (24.6%)
Following a low salt diet is too hard to understand (16.4%)
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6. Following a low salt diet takes too much time (14.7%)
The majority of responses for each of the barriers " Following a low salt diet costs too
much money, "Following a low salt diet takes too much time" and "Following a low salt
diet is too hard to understand" were negative. The majority of participants in this sample,
thereby, did not perceive these items as great barriers to dietary compliance.
Items "I cannot go out to many places too eat because of the low salt diet" and "Food

does not taste good on the low salt diet" are equivocal barriers to low salt diet
compliance, at best, as negative responses rival positive responses to each item. By

informal interview, many patients noted an "adjustment period" to incorporate the low
sodium diet. Perhaps the overall low perception of these items as diet compliance barriers
are secondary to the ubiquitous media messaging to eat healthy and mainstreaming into

popular culture of designer foods and special diets. The possibility may again be
entertained that specially managed heart failure patients have better regimen
understanding, knowledge and compliance.
Functional limitations
As noted previously, the NYHA classification system whereby one of four functional
classes is assigned to cardiac patients according to the degree of effort needed for their

symptom manifestation, has been criticized as subjective.
The consensus recommendations of the Advisory Council to Improve Outcomes
Nationwide in Heart Failure (ACTION HF) (1999) cites the NYHA classification system
as having a high degree of interobserver variability and as lacking the sensitivity to denote
small but significant clinical status changes though it is the most commonly used gauge of
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symptom severity in the evaluation of clinical status. This guideline also recommends
inquiry regarding symptoms experienced during activities of daily living and those that
impair functional status. A strategy of NYHA classes transcribed to reflect symptoms
experienced with activities of daily living was employed in this study to assess functional

limitations among heart failure patients as supported by expert panel review. Variability
may have been reduced by virtue of the fact that participants self reported

symptoms. Treatment of heart failure must, by necessity, be two pronged because
symptom evolution is known to be only weakly related to evolving cardiac dysfunction
therefore improving functional capacity alone is inadequate. A goal of treatment must
also be decreasing disease progression. Assessment of functional limitation as a measure
of clinical status is a "snapshot" of sorts; symptoms may change over time secondary to

medication effects, disease progression, concurrent illness or even heart failure etiology. It
is interesting to consider the individual heart failure patients functional limitations in light
of etiology of disease; heart failure secondary to substance abuse (alcohol or cocaine
cardiomyopathy) versus heart failure secondary to myocardial infarction from coronary
artery disease versus heart failure secondary to viral cardiomyopathy, for example. In an

assessment of patient perceived susceptibility/severity of heart failure, is patient's
experience with invasive diagnostics and interventions a potential influence on compliance
beliefs or behaviors ?
The fact remains that as the most frequently used gauge of clinical status in clinical
practice settings, as an outcome measure like worsening class level to denote a
decompensation or improving level as post intervention measure of specialized
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management efficacy, this classification system has merit and staying power.

Relationships between functional limitations and compliance beliefs
It is concluded that there is a positive relationship between patients' functional
limitations and perceptions of benefit from medication and dietary compliance. It is also

concluded that there is a negative relationship between patients' functional limitations and
perceptions of barrier to medication compliance. Though a single barrier to dietary
compliance scale item positively correlates with functional limitation, it is not conclusive

from this study to what extent functional limitation and perceptions of barrier to dietary
compliance are related. That the presence of symptoms exerts an affect on a patient's
perceived severity of illness charting a course for health action has been demonstrated

(Becker, 1974; Becker and Maiman, 1975). Therefore, demonstrated relationships of
symptom experience with other HBM variables like perception of benefit and barrier to a
recommended health behavior merit continued study in the effort to mediate compliance
(Becker and Maiman, 1975). Perceived benefits of compliance with medication by mean
subscale score demonstrated positive correlation with functional limitations while
perceived barriers to compliance with medication by mean subscale score demonstrated

negative correlation with functional limitations. Statistically significant relationships of
individual perceived benefits of medication compliance items ("IfI take my water pills, I
will lower my chance of being in the hospital" and "Taking my water pills lessens my

swelling") with functional limitations are logical and well demonstrated in this study. It
may be easily recognized that the more symptomatic patient would construe benefit from
decreased hospitalizations and less swelling. Demonstrated interitem correlations on the
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Beliefs about Medication Compliance Scale are again, logical on review. That these items
exist as perceived benefits/barriers to compliance and demonstrate relationships, may be
useful in the assessment of a heart failure patient's overall compliance belief set.

Compliance belief relationships may be important to individualizing patient teaching.
This study demonstrates individual barriers to compliance with medication compliance
items ("Taking water pills is hard to remember", "I have to take too many water pills each

day", "Taking water pills makes me worry about my heart disease" and "I forget to take
my water pills") are negatively correlated with functional limitation; again logical in that
the more symptomatic patient may perceive less barrier to medication compliance.
Regarding beliefs about dietary compliance, benefits subscale mean scores are close
to significantly correlated with functional limitation. If sample size were greater, statistical

significance may be demonstrated. No relationship with barriers to diet compliance
subscale mean scores is demonstrated here but preselected items were not perceived
greatly as barriers to dietary compliance in this sample. Clinically, therefore, the potential
for functional limitations to be related/influence perceived barriers to diet compliance,
may not be excluded. Individual benefits to diet compliance ("Eating a low salt diet will

keep me healthy" and "Eating a low salt diet will keep my heart healthy") demonstrate
strong and marginal positive correlation respectively, with functional limitation in this

study.
Individual barriers to dietary compliance item ("Salty food is not good for me")
demonstrates strong positive correlation with functional limitation in this study.
In conclusion, the Health Belief Model and the Bennett investigators in their
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instrument development study (1997) to measure compliance beliefs among heart failure
patients suggest those beliefs may differ according to patient's class of disease. The

findings of this small, pilot study support that suggestion.
Study power is only adequate (greater than .80 by convention) if a large effect size
is considered with this small sample (N=61, delta =.50, power =.96). A large effect size
was chosen by the principal investigator since Health Belief Model (HBM) variable testing
is not a new area of research and a review of the vast body of compliance literature is

supportive ofthe HBM variables, their relationships and influences on compliance beliefs
and behaviors. This investigator's clinical practice experience also supports the
assumption that symptoms' experience influences patients' compliance beliefs and
behaviors.
IMPLICATIONS
It is well known and revealed herein that compliance beliefs and behaviors are highly

complex. Implications for nursing practice are clear. Heart failure is a widespread and
growing problem.The latest consensus recommendations of the Advisory Council to

Improve Outcomes Nationwide in Heart Failure (ACTION HF, 1999) identify treatment
goals for this clinical syndrome; all of which may be mediated by patient compliance with
therapeutic regimen. This implies the necessity of strong consideration for patient

compliance issues and influences in nursing practice, education and in our efforts to
educate heart failure patients. Assessment of patients' beliefs is necessary to increase
patient involvement in the management of their chronic illness (Given et al, 1983).
Problems of health related behavior, like poor compliance with a low salt diet, for
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example, may be considered as symptoms leading the nurse to a behavioral diagnosis.
Again, thorough assessment of compliance beliefs and what may relate to those, is the

starting point for making a diagnosis and ultimately implementing treatment interventions
aimed at modifying compliance behaviors. (Jenkins, 1979).
LIMITATIONS
1.

Small sample size, so study lacks power.

2. Non random sample selection risking bias and erroneous findings.

3.Purely quantitative design with preselected benefit/barrier items limits potential findings
especially as the psychosocial nature of compliance beliefs increases their complexity and
variability among individuals, even those with a common illness.

RECOMMENDATIONS
1 . Use power analysis to determine adequate sample size for various effect sizes in order
to increase study power. The present study has strong clinical significance and a solid
theoretical basis which merits its repetition with a sample of at least 101 heart failure
patients ( With level of significance =.05, two tailed testing: N=101, medium effect size =

.30 yields power= .85; N=801, small effect size =.10, yields power =.80)
2. Randomize selection of heart failure patients for further study of HBM variables
influence on compliance beliefs and behaviors by selecting a sampling frame like a large

outpatient heart failure clinic, obtain a list of current patients, number them consecutively
and using a table of random numbers, draw at random, a sample of the desired size.

3. Triangulate the study design to obtain qualitative themes of benefit/barrier to
compliance with therapeutic regimen.
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4. Test further the reliability and validity of NYHA classification system for cardiac
disease as adapted in this study.

5. Assess patients' functional limitations and compliance beliefs as baseline to
customize teaching directed at influencing therapeutic regimen compliance.
6. Assess patients' experience with invasive diagnostics/interventions as potential
influences on perceived susceptibility/severity variable of HBM .
7. Increase nursing knowledge of patient compliance with therapeutic regimen: as
individual practitioners, and as a professional body, in the effort to affect positive

change in the treatment of chronic heart failure. Implement university curriculum and
clinical education addressing compliance as a modifiable behavioral response set.
8. Increase nursing knowledge of cultural, racial, and gender differences: as individual

practitioners, and as a professional body, in order to provide competent preventive care,
evaluation and management of heart failure. For example, develop and implement
sensitive tools in multiple languages to assess potential cross cultural differences in
compliance with low salt diet beliefs.
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Instructions: These are statements about your sex, race, age and symptoms of heart failure .
Please read the following three statements and circle one number for the choice after each
statement that best describes you. Following the fourth statement, please write your age in
years.

a. I am a: 1. Male

2. Female

b. My race is: 1. Hispanic 2. White Non-Hispanic 3.Black Non-Hispanic
4. American Indian 5. Asian 6. Other (Specify)
c. The best description of my functional capacity (my ability to do physical activity) is:

(CIRCLE ONE NUMBER ONLY BELOW)
1., have been told I have heart failure but it does not limit my physical activity.
2. I am comfortable at rest but walking 100 feet on level ground makes me feel: tired,
short of breath, like my heart beats too fast, like my heart beats irregularly, pressure in my

chest, pain in my chest, tightness in my chest.
3. I am comfortable at rest but getting dressed makes me fee: tired, short of breath, like
my heart beats too fast, like my heart beats irregularly, pressure in my chest, pain in my

chest, tightness in my chest.
4. Any physical activity makes me fee: tired, short of breath, like my heart beats too fast,

like my heart beats irregularly, pressure in my chest, pain in my chest, tightness in my chest

d. I am____ years old.
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ID#:

_________

Date:

Data Collected by:

________

BELIEFS ABOUT MEDICATIONS
INSTRUCTIONS: These are questions about the benefits of and barriers to taking your medicines,
especially your diuretics, or water pills. Please read each statement below and circle the number that best
describes how much you agree or disagree with the statement.

1.

1=
2=
3=

Strongly Disagree

4

Agree

5=

Strongly Agree

Disagree

Undecided

When I take mywater pills, Ido not worry asmuch about my heart

SD

D

U

A

SA

1

2

3

4

S

disease.
2.

If I take my water pills, I will lower my chance of being in the hospital.

1

2

3

4

5

3.

Taking water pills is hard to remember.

1

2

3

4

5

4.

Taking water pills is unpleasant.

1

2

3

4

5

5.

I have to take too many water pills each day.

1

2

3

4

5

6.

Taking water pills makes it hard to go away from home.

1

2

3

4

5

7.

Taking my water pills lessens my swelling.

1

2

3

4

5

8.

I forget to take my water pills.

1

2

3

4

5

9.

Taking water pills makes me worry about my heart disease.

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

10. Taking my water pills helps me breathe better.
11.
12..

Taking my medicine improves myquality of life.
Taking wter pills makes me ake u

at

night t go to the bathroom.
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ID#:

__________

Date:

_________

Data Collected

by:

BELIEFS ABOUT DIET
iNSTRUCTIONS: These are questions about the benefits of and barriers to following a low sodium (low
salt) diet. Please read each statement below andcircle the number that best describes how much you agree
or disagree with the statement.

1= Strongly Disagree

2
3=
4=
5=

Disagree
Undecided
Agree
Strongly Agree

SD

D

U

A

SA

1.

Eating a low salt diet will keep me healthy.

1

2

3

4

5

2.

Salty food is not good for me.

1

2

3

4

S

3.

Eating a low salt diet will keep my heart healthy.

1

2

3

4

5

4.

Eating a low salt diet will keep my swelling down.

1

2

3

4

5

5.

Eating a l

salt diet will keep fluid from building up in my body.

1

2

3

4

5

6.

I cannot go out to many places to eat because of the low salt diet.

1

2

3

4

5

7.

Food does not taste good on the low salt diet.

1

2

3

4

5

8.

Following a low salt diet costs too much money.

1

2

3

4

9.

Following a low salt diet takes too much time.

1

2

3

4

5

10. Following a low salt diet is too hard to understand.

1

2

3

4

S

1

2

3

4

5

1

2

3

4

11.

When Ifolilow myltowsalt diet, Ifeel better.

12. Eating a low salt diet will

Copyright C

help me breathe easier.
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FLORIDA INTERNATIONAL UNIVERSiTY
UNIVERSITY RESEARCH COUNCIL (URC)

APPLICATION FOR APPROVAL OF RESEARCH INVOLVING HUMAN
SUBJECTS
1. PROJECT TITLE: A descriptive correlation of medication and dietary compliance
beliefs with functional limitations in heart failure patients.
2. PRiNCIPAL INVESTIGATOR: Dorothy B. Diener RN, BSN SS#: 113-54-5772
Address: 4613 Bison St. Boca Raton, FL 33428 Phone: Home (561) 487-8322
(Voice Mail)
Position: [ ] Faculty [ X] Graduate student [ ] Undergraduate student
[ JOther
3. FACULTY SUPERVISOR (if PI is a student): Dr. Luz S. Porter, PhD, ARNP, FNP
4. STATUS OF PROJECT REVIEW:
[ X] New project [ ] Revision of pre ously approved project
[ ] Continuation of approved project
5.

BRIEF DESCRIPTION OF SUBJECTS
Number of subjects: 61
Check all of the following categories that describe your research subjects:
[X] Males
[X] Females
[ ] Minors (under 18 years old)
[

]

Students (Please specify):_

[ ] Persons With Physical Disablities (Please specify):
[ ] Persons With Mental/Psychological Disabilities
(Please specify):
[X] Persons With Physical or Mental Health Problems: Subjects will have a
medical diagnosis of heart failure
[ ] Persons With No Known Disabilities and No known health Problems
[ ] Prisoners
[ ] Pregnant women, fetuses, fetal material or placenta (Please specify):
[X]

Persons in some type of program: Outpatients of a S. Florida specialized heart

failure clinic program
[X] Other Pertinent Information: Subjects will be alert, oriented English speakers.
6.

TYPE OF REVIEW REQUESTED
[ ] Exempt: Category#(s)
[X I Expedited Review: Category # 9
]FulURC Reew
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7. RESEARCH OBJECTIVES
a. To determine heart failure clinic patients' beliefs about medication and dietary
compliance (Bene ,Milgro
Champion & Huster, 1997).
b. To determine if patient-reported functional limitations secondary to heart failure

relate to patient beliefs about medication and dietary compliance.
8. SUBJECT RECRUITMENT
Bennett et aL (1997) recruited 61 alert, oriented, English speaking patients with a
medical diagnosis of heart failure from a hospital's specialized outpatient clinic to
participate in the development of an instrument designed to measure beliefs about
compliance with medication and diet. I plan to obtain a convenience sample utilizing the
inclusion criteria of Bennett et a. (1997) by recruiting 61 alert, oriented English speaking

male and female patients, 18 years of age or older, diagnosed with heart failure from a,
South Florida outpatient heart failure clinic. Informed consent will be obtained prior to

inclusion in the study.
9. BENEFITS
a. No direct benefits will be promised to secure study participation. No direct benefits

will be received by those who choose to participate. Patients' routine heart failure

management will be unaffected by study participation.
b. The anticipated benefits of this research to society stems from its attempt to both

describe and explore what may potentially relate to compliance with treatment in the
practical management of a costly chronic illness. Assessing and utilizing heart failure

patients' beliefs about compliance with therapeutic regimen may allow practitioners to
better individualize educational interventions that ultimately increase compliance with
medication and diet. Increased compliance with therapeutic regimen may maximize the
individual's health potential by both promoting better health and preventing acute

decompensation and rehospitalization in the heart failure patient.
10. INFORMED CONSENT
A document detailing the nature and purpose of the study, its lack of direct risk and
benefit, the nature of participation and participant selection, a pledge of confidentiality and
contact information for direct access to the principal investigator will serve to inform

potential participants . Informed consent will be obtained from each participant by the
principal investigator.
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11. CONFIDENTIALITY OF DATA
All participants will be assured that information obtained in the course of this study
will be kept strictly confidential and all data received by the clinic practitioner and/or
principal investigator will only be handled by the principal investigator, major professor
and statistician.Participants will be assured of questionnaire anomymity and will not be
asked to indicate their names on any portion of e questionaire packet. Participants will
be assured that all results will be reported as group data. No information will be released
or published in which individual participant's names or identifying data will be disclosed.
Completed questionnaires returned to clinic practitioners will be retained on site in a
locked box for weekly collection by the principal investigator. A five to ten week time

frame is estimated to obtain 61 study participants. All questionnaires will be secured by the
principal investigator and stored in a locked cabinet for a minimum of three years in the
investigator's home.
12. METHOD AND PROCEDURE
Approval of this research protocol and permission to conduct the study will be
obtained from Florida International University and the research review committee ofthe
agency from which participants will be recruited.
Informed heart failure clinic patients who indicate their consent to participate will be
instructed to complete:.
a. a demographic questionnaire
b. the Beliefs about Medication Compliance Scale (BMCS)
c. the Beliefs about Dietary Compliance Scale (BDCS)
Each questionnaire contains instructions to participants for its completion.

Questionnaire completion should take approximately 15-20 minutes.
13. STIMULUS MATERIALS
Instruments:
a. Demographics.
Participants will indicate their race, sex, age and New York Heart Association (NYHA)
class 1-I operationalized to indicate functional capacity. Content validity of
operationalized NYHA class levels is supported by expert panel review.
b.Beliefs about Medication Compliance Scale (BMCS)
Beliefs about Dietary Compliance Scale (BDCS)
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Participants will use a five point scale (1=strongly disagree, to 5=tongly agree)to
indicate response to items designed to measure perceived benefits and perceived barriers
to compliance with both medication and dietary regimen central to heart failure
management (Bennett et aL., 1997).

13. STIMULUS MATERIALS
Instruments continued:
A content validity index of 0.81 was reported and construct validity of both the BMCS

and BDCS was supported by factor analysis (Bennett et al., 1997). "Internal consistency
reliabilities of the perceived benefits and barriers subscales of the BMCS and BDCS were
computed using Cronbach's alpha statistic" with reported values ranging from 0.68 to
0.91 (Bennett et al., 1997, p.277).
14. RISKS TO SUBJECTS
Participants will not be subject to any physical contact nor experimental manipulation
in this study. Neither will participants be subject to any social repercussions, economic
demands, psychological risks or legal liabilities in this study. The letter of introduction will
clearly inform potential subjects that study participation is wholly voluntary.
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Wednesday, January 27,99
Dr.Susan J. Bemnett, DNS
Indiana U versity
School of Nursing
li
Middle Dr.
Indianapolis, IN 46202

Dear Dr. Bennett:
Please allow this letter to serve as my introduction. I am a registered nurse currently pur4ng

my master's degree in nursing science at Florida International University in North Miami. I reside
in South Florida and work as a full time staff nurse (CCU/CVICU) at a large, urban, tax assisted
teaching hospital here. lan writing to express my great interest in the instrument you developed

to measure heart failure patients' compliance beliefs as puiblished in Heart & Lung, July/August,
1997.

With your permission, I would like to replicate the use of both your Beliefs about Medication

Compliance and Beliefs about Dietary Compliance Scales as they appear in Heart & Lung, inmy
master's thesis this year. I am currently completing my research proposal.

I plan to distribute the scales in my hospital district's outpatient heart failure clinic. While
waiting to see the advanced practice nurses who provide care in the clinic, the patient's will be
offered the opportunity to participate in my study and indicate their beliefs about medication and
diet compliance by completing your scales. Our population here is representative of multiple races
and cultures lending diversity to the study.
In addition to replicating the use of your scales to generate descriptive data, I plan to explore
the relationship, if any, between a heart failure patient's scale scores and their functional capacity

by NYHA class. I seek to answer the following question: Is there a relationship between scale
scores meamiing beliefs about treatment compliance and functional limitations in people with
heart failure?
I appreciate your consideration in this matter and shall look forward to your reply. My email
and street addresses as well as my telephone number which includes voice messaging are enclosed
for your convenience. Thank you and best regards.

Sincerely,
Dorothy Diener, RN
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Subj:

Scales

Date: 99-02-04 13:50:39 EST
From: sbennet@iupui.edu (Bennett, Susan J)
To: mtarkus@aol.com Cmtarkus@aol.com)
Dorothy, I received your request for the Belief Scales and am sending you
the information by U.S. mail today. Susan Bennett

Susan J. Bennett, DNS, RN
Associate Prfessor
Indiana Uniwrsity School of Nursing
1111 Middle Drive
Indianaporis, IN 40202
(317) 274-4432 (telephone)
(317) 278-1856 (Fax)
sbennet@upui.edu <mailto:sbennet@iupul.edu> (e-Qail)

Headers
Retum-Path: <sbennet@iupui.edu>
Received: from ry-yc02.mx .aol.com (rly-ycO2.mail.aol.com [172.18.149.34]) by air-yc02.mall.aol.com (v56.24) with SMiP
Thu, 04 Feb 1999 13:50:39 -0500
Received: from iris.iupul.edu (iris.iupui.edu [134.68.220.32]) by rly-ycO2.mx.aol.com (x) with SMTP; Thu, 04 Feb 1999
13:50:11 -0500
Receivd: from lynx.uits.iupui.edu (lynx.uits.iupui.edu [134.68.220.22])
by iris.iupui.edu (8.9.1a/8.9.1/1.18IUPUIPO) with ESMTP id NAA20783
for <mtarkus@aol.com>; Thu, 4 Feb 1999 13:50:10 -0500 (EST)
Received: by lynx.uits.iupui.edu with Internet Mail Serice (5.5.2448.0)
id <1DTDBSAV>; Thu, 4 Feb 1999 13:50:10 -0500
Message-ID: <CD5DFED91D8ED21198C30008C74C7A08B6741D jaguar.uits.iupui.edu>
From: "Bennett, Susan J" <sbennet iupu.edu>
To: "'mtarkus@aol.com" <mtarkus aol.com>
Subject: Scales
Date: Thu, 4 Feb 1999 13:50:09 -0500
MIME-Version: 1.0
X-Mailer Internet Mail Ser ce (5.5.2448.0)
Content-Type: text/plain

SwndP Pdowbuey7, 1386

100

Amedlc

11mw MTARKUS

P ge

INDIANAUNIVERSTY

SCHOOL OF NURsING

February 4, 1999
Dorothy Diener, RN
4613 Bison Street
Boca Raton, FL 33428
Dear Ms. Diener:
You have my permission to use the Beliefs about Medication Compliance Scale

and the Beliefs about Dietary Compliance Scales for your master's degree research
project. I have enclosed current copies of the Scales as well as scoring
instructions. Additionally, we have developed a third scale entitled Beliefs about
Self-Monitoring. I have enclosed a copy of this scale, too. The self-monitoring

scale is being testing for reliability this semester by a graduate nursing student in
Indiana. You are welcome to include this scale, too. If you do, please send me
information regarding the reliability of the scale in your sample.
Best wishes with your research project. Feel free to contact me if you need
additional information.

Sincerely,

Susan

J. Bennett,

DNS, RN

Associate Professor

DE)ATii OF Anua HEAn
1111 Middle Drive

Indianapolis, Indiana
46202-5107
317-274-0024
Fax: 317-278-1856
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Health Belief Seslej and Scoring

Yuji-ructions

developed
Susan

Bennett,

WNTS'

RN

Indiana University School of Nuning

J. j3ennetU DNS9
f Susan
o
For additional Information,'plesse
IndLanspolis,
r.,
diddle
1111
i
:
University
Telephone - (317) 274-4432; Faz - (317) 278-1356; E-mail Copyright 0

AAuguit

1998 Susan J. Bennettq
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IRS,

RN,

Associate

r,
.

t

sbennet@1upuLedu

Indij

Instructions for Scoring the Beliefs About Compliance Scales
Susan J. Bennett, DNS, RN.
Each Belief Scale has two scores: A Benefits Score and a Barriers Score. Scores are obtained as follows:
1.

Score all individual items as:
1= "Strongly Disagree"

2 "Disagree"

3 ="Undecided"
4="Agree"
5="Strongly Agree"
2.

Reverse code item 9 on the Beliefs About Medications Scale.

3.

Reverse code item 2 on the Beliefs About Diet Scale.

4.

Compute a Benefits Score and a Barriers Score for each instrument by summing individual items of
each subscale. The subscales for the Medication and Diet Scales are identified in the article by
Bennett, Milgrom, Champion, and Huster, Heart and Lung, 1997, Volume 26, pp. 273'9. The

subscales for the Self-monitoring Scale are enclosed.
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Benefits and Barriers Coding Sheet
Besefit

1.

When I take my water pills, I do not worry as much about my heart disease

Benefit

2..

If! take my water pills, I wil lower my chance of being in the hospital.

BarrIer

3.

Taking water pills is hard to renember.

Barrier

4.

Taking water pills is unpleasant.

Barrier

5.

I have to take too many water pills each day.

Barrier

6.

Taking water pills makes it hard to go away from home.

Benefit

7.

Taking my water pills iessans my swelling.

Barrier

S.

I forget to take my water pills.

Beueflt*

9.

Taking water pills makes me worry about my heart disease.

Benefit

10.

Taking my water pills helps me breathe better,

Benefit

11. Taking my medicine improves my quality of Life.

Barrier

12. Tain

ter

pills maer m

Recode 9 when scoring

CopynghtO 1998 Susan J. Bennett, DNS. N
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aepa night to go to the bathro.

BELEEFS ABOUT DIET
Benefits and Barriers Coding Sh"t
Wthy-

-t

t.

BentfIte

2.

Salty food is not good

Beaefit

3.

Eating a low salt diet will keep my heart healthy.

BenefIt

4.

Eating a low

t

diet will keep my swvIlLng down.

Benefit

5.

Eating a low

t

diet will keep BuW fiwn building

'Barrier

6.

1 emm

Barrier

S.

Following a low Wt diet costs too much money.

Barrier

9.

Following

Barrier

10. Following a low

Benefit

11. When I follow my low salt diet I fed beur,

Benefit

*

%,W

Benefit

1.

wag

Ong

l

or

.

go out to many phca to nt because of dw low salt diet.
Barrier 7. Food does not Uste good otld

l

low salt

'

t

diet ukes too much

t

did

ill

-A

'

h

when scodng

199

.

DNS. RN
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15. AFFIRMATION OF CONLIANCE AND ACCEPTANCE OF RESPONS mTY

I agree to follow the procedures outlined in this summary description and any attachments. I

understand that no contact may be initiated with subjects until I have received approval of these
procedures from the URC and have complied with any modifications required in connection with
that approval. I understand that additions to or changes in the procedures involving human
subjects can only be made afier approval of the URC. I understand that I must promptly report to
the URC any problems with the rights or welfare of the human subjects. I understand and will
follow Florida International University's policies concerning research with human subjects. I will
do everything in my power to protect the rights and welfare of human subjects in my research
project.

A decrpive corrlatio of mdction an ditar c mp
in

heart faiu r

Signature ofPr

a

ce bliefs with fuctiona limitations

(print title of project here)

t

Dat

ph Investigator

Dorothy B. Diener RN. BSN
Printed name of Principal Investigator
If the PI is a student, the faculty supervisor must sign below.
I have read this application and assume responsibility for its accuracy and for supervision of the
pro sed resear h oject.
Signa re of Fau t

ate

upervisor

Printed name of Faculty Supervisor
ACTION RECOMMENDED BY URC **For URC use only*
Date

jj

[j4proved

Signaur~ of Lr C C

[

Changes/Clarifications Requested [

Require Full Board

Review
i

a~rest

Printed 'name of URC Chairperson
Date:________ [ ] Approved f ] Changes/Clarifications Requested [

Require Full Board
Review

Signature of URC Chairperson
Date:________ [ ] Approved [] Changes/Clarifications Requested ( ] Require Full Board
Review
Signature of URC Chairperson
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The Public Univeny atAfmi

Date:

September 10, 1999

To:

Dorothy B. Diener, RN, BSN, Master's Student
Dr. Luz Porter, Professor and Chair: Thesis/Research Project

From:

Douglas A

o

,

.,

P

SON URC Representative
Re:

Application for approval of research involving human subjects titled: "A
descriptive correlation of medication and dietary compliance beliefs th

functional limitations in heart failure patients."
Cc: URC Chairperson
Your application has been approved for exempt and/or expedited status. Please be aware
that you have agreed to follow the procedures outlined in your summary description and any
attachments. You may not contact subjects until you have received this written notification of
approval. You understand that any additions to or changes in the procedures involving human
subjects can only be made after approval of the URC or its departmental representatives. You
understand that you must promptly report to the URC any problems with the rights or welfare of

the human subjects. You understand and will follow Florida International University's polices
and procedures concerning research with human subjects. You will do everything with your
power to protect the rights and welfare of human subjects in your research project.
Good luck on your project/research and congratulations.

School of Nursing
North Campus, North Miami, Florida 33181
(305) 919-5915 oTDD, via FRS 1-800-955-8771 - FAX (305) 919-5395
Equal Opportunty/Equal Access
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Employer

and Institution

Broward General
Medical Center
Region
December 15, 1999

1600 S.Andrews Ave., Ft. Lauderdale, FL 33316

*

(954) 355-4400

Dorothy B. Diener, RN, BSN
4613 Bison Street

Boca Raton, FL 33428

SUBJECT:

A descriptive correlation of medication and dietary compliance beliefs with functional
limitations in heart failure patients.
Correction of date

Follow

up

October

20,

1999

meeting.

Dear Mrs. Diener:
At its meeting on October 20, 1999, the Institutional Review Board (IRB) of Broward General Medical
Center reviewed the protocol and the letter of introduction related to the above named research
proposal. After discussion of this matter, the IRB reviewed and approved the proposal. The informed
consent was approved contingent upon the following revision.
1.

Please delete this paragraph " I am hopeful that information obtained from this study will assist
nurse educators to better teach patients to manage their heart failure. Thank you for you interest
and consideration."
2. Revised the last sentence to indicate that the researcher has explained the research procedure, a
copy of the informed consent has been offered, and that the participant agrees to participate.
This study has been approved for one year, and the next progress report is due before October 20,

2000.
In addition you are required to:
*

Promptly report to the IRB any changes in research activity including protocol closure,

E Ensure that changes in the approved research during the period for IRB approval has already been
given may not be initiated without IRB review and approval unless where necessary to eliminate
*

apparent hazard to the human subjects,
Prompt report unanticipated problems involving risk to human subjects or others.

The IRB of Broward General Medical Center has the authority to have a third party observe the consent
process and the research.
This IRB is in conformance with the requirements in Title 21, Part 56, Sub-Part A-D, of the Code of
Federal Regulations published April 1, 1996.
Sincerely,

Phyli T mcyk,PharmD

Coordinator - T3451
North Broward Hospital District
H:\IRB\DIBNER-DEC1999

A facility of the Norib Broward HospitalDistrict. The Nortb Broward HospitalDistrictis affiliated with the University ofFlorida and
Nova Southeastern Colleges of Medicine and is an equal opportunity employer and affirmative action procurer ofgoods and services.
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